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Abstract: Arteriogenesis is the process by which mature arteries form from collateral 
arterioles after upstream arterial stenosis or occlusion. During collateral remodeling, 
monocytes are recruited to the vessel wall. Placental growth factor (PLGF) is a potent 
stimulator of arteriogenesis via monocyte recruitment. Although fluid shear stress (FSS) 
is thought to be the primary signal for arteriogenesis, its role in regulating PLGF 
expression is unknown. However, PLGF is increased in collaterals by upstream arterial 
ligation. Therefore, we hypothesized that PLGF expression is regulated by FSS. To test 
this hypothesis, we created an in vitro model of coronary vessels, consisting of human 
coronary artery endothelial cells (HCAEC) and human coronary artery smooth muscle 
cells (HCASMC) cocultured on porous Transwell inserts. We used a cone and plate 
apparatus to expose the HCAEC of the coculture to different FSS waveforms. We also 
employed an ex vivo model consisting of isolated mesenteric arterioles perfused at 
various flow rates. Flow or FSS significantly increased PLGF expression at both the 
mRNA and protein level, and this effect was dependent on the duration and magnitude of 
FSS, confirming our hypothesis. PLGF was predominantly produced by HCAEC, but 
HCASMC also played a role in modulating HCAEC PLGF expression and response to 
FSS. Next, we set out to identify the signaling pathways mediating the effects of FSS on 
PLGF. Hydrogen peroxide and NADPH oxidase 4 were required for FSS to upregulate 
PLGF. Similarly, heme oxygenase 1 activity was also required for FSS to affect PLGF 
expression. Heme oxygenase 1 also mediated the effects of hypoxia on PLGF, and our 
studies suggest the existence of a common pathway between these two stimuli (FSS and 
hypoxia). This study builds on several recent studies using various redox knockout mice 
to study vascular remodeling. It further emphasizes the importance of PLGF for 
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Ischemic cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
western and developing countries, and even optimistic projections predict it to remain so for the 
foreseeable future 
1
. Ischemic CVD results from narrowing of the coronary arteries due to buildup 
of atherosclerotic plaque in the vessel wall.  
Arteriogenesis is the process by which mature arteries form from collateral arterioles 
after upstream arterial stenosis or occlusion. Collateral arterioles are interconnecting, narrow-
diameter vessels that carry little blood under normal conditions due to their high resistance. 
Arteriogenesis can potentially reestablish flow to sites downstream of an occlusion, preventing 
ischemic injury. Thus, pharmacological stimulation or enhancement of arteriogenesis would 
provide a non-invasive treatment for ischemic CVD. For such a treatment to be safe and effective, 
comprehensive understanding of the mechanisms of arteriogenesis is required. Although 
arteriogenesis does occur in regions of tissue hypoxia, It more often occurs upstream of the 
ischemic region 
2
. Flow-limiting occlusions cause an increase in the pressure gradient across the 
collaterals, which results in increased fluid shear stress (FSS) on the collateral wall
3
. FSS is 
thought to be the primary signal for arteriogenesis. 
2 
 
Placental growth factor (PLGF) is a potent arteriogenic factor (more so than the related 
protein VEGF-A, which mainly induces capillary proliferation). PLGF knockout in mice has little 
effect on vascular development, but results in impaired collateral growth in adults
4
. Ligation of the 
femoral artery in rats to induce collateral growth results in increased PLGF expression
5
, and 
overexpression of PLGF in mice results in increased vascularization
6
. Furthermore, PLGF selectively 
increases the size of vessels with a diameter of 96-136 μm, the size range of collateral arterioles
7
. 
These findings demonstrate the key role of PLGF in arteriogenesis. 
During collateral remodeling, monocytes are recruited to the vessel wall. The importance of 
monocytes to arteriogenesis was demonstrated in mutant mice with severely reduced circulating 
monocyte levels. These mice have impaired collateral remodeling in the ischemic hindlimb
8
. 
Interestingly, monocyte recruitment is diminished in PLGF gene knockout mice
9
, and Pipp et al. have 
shown that the arteriogenic properties of PLGF are dependent on monocytes
10
. PLGF also enhances 




Although the work cited above provides convincing evidence that PLGF plays a central role 
in arteriogenesis, the regulatory mechanisms controlling PLGF expression are poorly understood, 
especially in the vascular wall. The profound effect that shear stress has on regulating arteriogenesis 
has led us to hypothesize that PLGF expression in vascular cells is regulated by FSS.  
 To test our hypothesis we established two models of the vessel wall. The first model 
consisted of human primary coronary artery endothelial cells and smooth muscle cells cultured on 
either side a porous membrane insert.  FSS was applied to the endothelial cells using a cone driven by 
an electrical stepping motor. In the second model mesenteric arterioles were mounted on glass 
cannula and perfused by altering the upstream and downstream pressure. We then determined the 
effects of physiologically relevant FSS waveforms on PLGF expression and characterized signaling 








1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 
2030. PLoS Med. 2006;3:e442 
2. Schaper W, Scholz D. Factors regulating arteriogenesis. Arteriosclerosis, Thrombosis, and 
Vascular Biology. 2003;23:1143-1151 
3. Unthank JL, Nixon JC, Burkhart HM, Fath SW, Dalsing MC. Early collateral and 
microvascular adaptations to intestinal artery occlusion in rat. Am.J.Physiol. 1996;271:H914-
H923 
4. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, 
Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, 
Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, 
Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between 
vascular endothelial growth factor and placental growth factor contributes to angiogenesis 
and plasma extravasation in pathological conditions. Nature Medicine. 2001;7:575-583 
5. Prior BM, Lloyd PG, Ren J, Li H, Yang HT, Laughlin MH, Terjung RL. Time course of 
changes in collateral blood flow and isolated vessel size and gene expression after femoral 
artery occlusion in rats. American Journal of Physiology Heart and Circulatory Physiology. 
2004;287:H2434-H2447 
6. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, Failla CM, 
Zambruno G. Mice overexpressing placenta growth factor exhibit increased vascularization 
and vessel permeability. Journal of Cell Science. 2002;115:2559-2567 
7. Li W, Shen W, Gill R, Corbly A, Jones B, Belagaje R, Zhang Y, Tang S, Chen Y, Zhai Y, 
Wang G, Wagle A, Hui K, Westmore M, Hanson J, Chen YF, Simons M, Singh J. High-
resolution quantitative computed tomography demonstrating selective enhancement of 
medium-size collaterals by placental growth factor-1 in the mouse ischemic hindlimb. 
Circulation. 2006;113:2445-2453 
8. Bergmann CE, Hoefer IE, Meder B, Roth H, van RN, Breit SM, Jost MM, Aharinejad S, 
Hartmann S, Buschmann IR. Arteriogenesis depends on circulating monocytes and 
macrophage accumulation and is severely depressed in op/op mice. J.Leukoc.Biol. 
2006;80:59-65 
9. Scholz D, Elsaesser H, Sauer A, Friedrich C, Luttun A, Carmeliet P, Schaper W. Bone 
marrow transplantation abolishes inhibition of arteriogenesis in placenta growth factor (plgf) 
-/- mice. Journal of Molecular and Cellular Cardiology. 2003;35:177-184 
10. Pipp F, Heil M, Issbrucker K, Ziegelhoeffer T, Martin S, van den Heuvel J, Weich H, 
Fernandez B, Golomb G, Carmeliet P, Schaper W, Clauss M. Vegfr-1-selective vegf 
homologue plgf is arteriogenic: Evidence for a monocyte-mediated mechanism. Circulation 
Research. 2003;92:378-385 
11. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, 
Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, 
Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P. Revascularization of 
ischemic tissues by plgf treatment, and inhibition of tumor angiogenesis, arthritis and 





REVIEW OF LITERATURE 
Ischemic Heart disease (IHD) is the leading cause of morbidity and mortality in western 
and developing countries, and even optimistic projections predict it to remain so for the 
foreseeable future
1
. The leading cause of IHD is obstructive atherosclerosis
2
.  Atherosclerosis is 
an occlusive vascular disease characterized by abnormal inward growth of arteries along with 
accumulation of lipids (mainly cholesterol) inside these lesions.   
Vessels consist of three overlaid layers from the inside outwards these are the tunica 
intima, tunica media, and tunica adventitia. The inner most layer, the intima, consists of a 
cobblestone monolayer of endothelial cells (EC), around which, is a fine meshwork of 
extracellular matrix (ECM) proteins forming a basement membrane (Fig. 1). Around this ECM 
component is yet another thicker fenestrated ECM layer called the internal elastic lamina, which 
delineates the divide between tunica intima and tunica media. The tunica media is mostly 
composed of smooth muscle cells (SMCs) arranged circumferentially and ECM proteins. This 
muscular layer is thicker in arteries that withstand high arterial pressures compared to the lower 
venous pressure of the veins. In larger vessels, another thick fenestrated ECM layer, the external 
elastic lamina, covers the outer layer of the tunica media. The tunica adventitia is mostly 
comprised of collagen fibers, fibroblasts, and macrophages. In larger vessels with thick media, 
diffusion of oxygen and nutrients across the intima is insufficient. As a result the adventitia of 
these vessels contains small arterioles called the vasa vasorum that supply the outer layer of the 




Figure 1. Structure of the arterial wall. This illustration shows one side of the arterial wall the 
innermost layer (intima) is at the top while the outermost layer (adventitia) is at the bottom.   
Atherosclerosis 
During atherosclerosis repetitive injury of the endothelium leads to endothelial 
dysfunction. This causes increased permeability of the endothelium and the adhesion of 
leukocytes and platelets. Concurrently, low-density lipoprotein LDL accumulates in the sub-
endothelial basement membrane (Fig. 2). The release of enzymes such as myeloperoxidase and 
lipoxygenases by leukocytes, along with increased reactive oxygen species results in the 
oxidation of LDL, which in turn triggers the upregulation of growth factors, adhesion molecules 
and cytokines in the endothelium. These cause an increase in the inflammatory state of the vessel 
and further recruit leukocytes. Monocytes recruited to the area differentiate into macrophages 
after extravasation. These macrophages phagocytose the oxidized LDL. Macrophages that 
accumulate oxidized LDL become foam cells and release further cytokines. Initially, a non-
protruding fatty streak develops consisting of few foam cells where the majority of lipids are 
intracellular. As more oxidized lipids accumulate, further aggravation of the inflammatory 
process ensues and increased release of growth factors and cytokines results in the increased 
motility and proliferation of SMC. This proliferative synthetic phenotype of SMCs produces 
6 
 
excessive amounts of collagen. This leads to the thickening of the intima. The lesion now intrudes 
into the lumen, resulting in narrowing of the lumen and disturbed flow. The turbulent flow further 
exasperates endothelial dysfunction, leading to further accumulation of oxidized LDL. The 
increased involvement of SMC, along with extracellular accumulation of oxidized LDL and 
necrotic cell debris results in the progression of the fatty streak into an atherosclerotic plaque.      
 
Figure 2. Illustration of the progression of atherosclerosis. Modified from Yu and Rifai 2000 
Clinical Biochemistry, 33 (8); 601 - 610 
 
The plaque continues to accumulate lipids, foam cells, SMC, collagen and inflammatory 
cells. This along with the cytotoxic effects of oxidized LDL induces apoptosis in SMCs and 
degradation of the fibrous cap. These processes result in structural weakening, leading to a plaque 
vulnerable to rupture. Plaque constituents are highly thrombogenic, rupture releases these 
materials into the blood stream resulting in thrombosis of the vessel and ischemia of the 
downstream tissue. The thrombus may result in incomplete occlusion, in which case the thrombus 
7 
 
is organized and included into the plaque further increasing the size and intrusion of the plaque. 
Atherosclerotic plaque also may fragment releasing fibrous lipid emboli that cause damage 
further downstream in the circulation. Finally, as lesions increase in size they weaken the vessel 
wall, which may lead to aneurysm and rupture of the vessel. 
Atherosclerosis shows a tendency to develop in areas of disturbed flow, such as 
bifurcations and curvatures. Indeed, turbulent flow causes endothelial dysfunction in vitro
12
. 
Hyperlipidemia is also an important factor in the development of atherosclerosis, not only for the 
obvious increase in the lipids that accumulate in lesions. Increased circulating lipids also lead to 
endothelial dysfunction and increased production of reactive oxygen species. 
In the coronary setting atherosclerosis can have deleterious consequences. In the early 
stages of stenosis, chest pain as the result of ischemia known as angina pectoris is brought on by 
exertion know as effort angina. As the lesion continues to grow it may rupture resulting in 
thrombosis and myocardial infarction or if incompletely occluded progresses into increasing chest 
pain at rest, termed crescendo angina. At this point, continued growth of the lesion results in 
increased ischemic damage to the myocardium, leading to hypertrophy as more damage 
accumulates. Decompensation and ultimately heart failure ensue.  
Treatment of fully developed symptomatic atherosclerotic plaque currently requires 
surgical intervention. The two most common procedures are coronary angioplasty and coronary 
artery bypass graft (CABG) surgery. Coronary angioplasty involves the use of a catheter to 
position a balloon next to the atherosclerotic lesion. The balloon is then inflated, pushing the 
lesion into the vessel wall and increasing the luminal surface area. The balloon is then deflated 
and removed. Another common procedure is to implant a mesh tube known as a stent to support 
the vessel wall. Stents are more cost effective and less invasive than CABG surgery
13
. 
Unfortunately, in-stent stenosis or “restenosis” occurs in 36% of patients
5
. Restenosis is the 
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narrowing of a vessel at the site of stent implantation the mechanisms of which are varied. 
Excessive expansion of the stent can cause injury to several layers of the vessel, which exposes 
several of the factors that initially drive atherosclerosis and is correlated with lesion 
regeneration
14
. Vessel injury results in the exposure of tissue factor which promotes thrombus 
formation
15
. SMC invade the thrombus and deposit ECM proteins leading to the reorganization 
and incorporation into the vessel wall
16
. Furthermore, the injured vessel releases several pro 
inflammatory molecules that promote the recruitment of leukocytes further driving the 
remodeling and intimal thickening
17
. The application of drug eluting stents has shown great 
promise in reducing in-stent stenosis. These stents release a drug locally to inhibit the processes 
that lead to in-stent restenosis. Drug eluting stents result in improved out come with an average 
reduction of 10% in stent restenosis 
5,10
. 
 Coronary artery bypass graft surgery is the autologous transplantation of a vessel to the 
coronary circulation in order to bypass a stenotic artery. This procedure is invasive and requires 
opening the chest cavity and stopping the heart. Commonly harvested vessels are the internal 
mammary artery (IMA) and the saphenous vein (SV). CABG is an expensive and invasive 
procedure with several possible complications including neurocognitive decline as a result of 
cerebral damage
18
. Patency of the grafted vessel after surgery is a key prognostic indicator. IMA 
grafts show significantly increased patency compared to the SV grafts 10 years after surgery 
(95% vs. 60%, respectively)
19
. This increased stenosis of the SV grafts is the result of intimal 
thickening arising from SMC proliferation 
13,14
. Evidence suggests the stimulating force behind 
this proliferation is the difference in hemodynamic forces between venous and arterial branches 
13-16
. Increased stenosis of the SV graft requires intervention by SV graft angioplasty. This 
procedure is similar to coronary angioplasty but also includes several additional complications. 
Veins are slower at lipolysis 
20
and have a higher rate of liposynthesis
21
. This results in SV graft 
lesions being more diffuse and friable than arterial plaque
22-25
. SV graft lesions also have a higher 
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content of foam and inflammatory cells 
25
, increasing the chance of complications caused by the 
release of lipid emboli and lesion debris into the bloodstream 
26
. Furthermore, LSV grafts exhibit 
a higher frequency of in stent stenosis than native arteries 
27
. 
 Arteriogenesis  
 Collateral vessels are small interconnecting arterioles that connect tissues perfused by 
two different conducting arteries. These narrow diameter vessels carry little blood due to their 
high resistance. When a conducting artery is occluded, the pressure downstream of the occlusion 
is greatly reduced. The resultant pressure gradient increases flow through the collateral vessels to 
the lower pressure area. As this flow is maintained, an increase in the diameter of the collateral 
vessels is observed (Fig. 3). This increase is due to active remodeling of the vessel and not merely 
vasodilatation
28
. Additionally, these expanded vessels are stable, functional, and in the coronary 
circulation ameliorate some of the effects of myocardial ischemia
29, 30
. This outward remodeling 
of preexisting collateral vessels into mature patent conductance arteries was termed arteriogenesis 
31
. This process is not to be confused with angiogenesis, which is the sprouting of endothelial 
cells from preexisting vessels to form new capillaries
32
. Arteriogenesis progresses through three 
stages. The first stage, initiation, involves the release of chemokines, upregulation of adhesion 
molecules and changes in the ECM. This is followed by the growth phase, in which recruitment 
of monocytes results in significant SMC migration and proliferation and continued change in the 
ECM. An increase in the area of the lumen and length of the vessel is observed. Finally, 
maturation or stabilization of the vessel occurs in which the SMCs return to a contractile rather 




Figure 3. Illustration of arteriogenesis.  
 
 Initiating collateral growth 
 Identifying the initiating stimulus of collateral growth and characterizing how it affects 
the vessel wall is essential to develop a therapeutic compound that stimulates arteriogenesis. The 
two major factors that change during CAD are discussed below.   
 Tissue ischemia 
 Occlusion of an artery results in low perfusion of the downstream tissue, as oxygen is 
depleted from the tissue, hypoxia ensues, resulting in the stabilization of the nuclear factor 
hypoxia inducible factor-1 (HIF-1)
30,31
. HIF-1 upregulates vascular endothelial growth factor 
VEGF
33
. HIF-1 also activates members of the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) family
34
.  NF-κB regulates several inflammatory responses
35, 36
 which 
are conducive to vascular remodeling.  
11 
 
 Most of the arteriogenic effects of hypoxia are attributed to the upregulation of VEGF, 
which is a potent angiogenic factor. VEGF was first described as vascular permeability factor. A 
protein identified in the fluid accumulated in the interstitial space of tumors. This protein 
increased the permeability of vessels
37
. VEGF was then identified as a heparin binding secreted 
endothelial mitogen that induced angiogenesis in vivo
38
 and induced angiogenesis in tumors 
39
. 
VEGF binds to the receptors VEGFR-1, VEGFR-2, VEGFR-3, and neuropilin-1
40-43
. VEGF 
deficient mice develop with abnormal vasculature that leads to embryonic lethality
44, 45
. There are 
several isoforms of VEGF; A, B, C, D, E and Placental growth factor (PLGF). VEGF-A has 
multiple splice variants with varying degrees of expression 
45
.  
 Administering VEGF after occlusion of the left circumflex coronary artery in canine 
hearts resulted in an increase in the flow restoration compare to untreated dogs
46
.  In the porcine 
heart occlusion of the left circumflex coronary artery resulted in a marked increase in VEGF 
expression in the myocardium
47
. Treatment with VEGF resulted in a significant increase in flow 
restoration compared to untreated controls. However, VEGF treatment also causes excessive 
hypotension
48
. Both VEGF treatment and VEGF gene transfection increases collateral growth in 
the peripheral circulation of rabbits following femoral artery ligation and causes collateral growth 
and flow recovery
49, 50
. A marked increase in the density of the capillary beds of the calf were also 
noted
49, 51
. In contrast to these findings, VEGF treatment in the canine heart after left circumflex 
coronary artery ligation had no effect on flow restoration or collateral size
52
. Additionally, the 
more troubling finding that VEGF caused accelerated intimal thickening at sites of vascular 
injury was reported
53
. Similarly, adenoviral induced over expression of VEGF had no arteriogenic 
effect in either the porcine coronary circulation after coronary occlusion or the rabbit hind limb 
after femoral artery occlusion
52
. These inconsistencies in the effects of VEGF may be attributable 
to varying surgical protocols, VEGF administration, or possibly, a temporal factor such as how 
long after the procedure was VEGF treatment commenced. 
12 
 
 The arteriogenic effect of VEGF may be the result of its ability to induce upregulation of 
integrin expression on the surface of the endothelium 
53
. Integrins play a critical role in both 
sensing arteriogenic stimuli and coordinating the remodeling process (see below). Similarly, 
VEGF signaling increases VE-cadherin phosphorylation
54
. VE-cadherin is important in 
mechanotransduction and endothelial permeability. VEGF also causes an increase in matrix 
metalloproteinase (MMPs)
54
 expression. MMPs are instrumental in the remodeling of ECM 
during collateral growth (see below). Additionally, VEGF induces vasodilatation
55
 by increasing 
nitric oxide (NO) production
56, 57
. NO production is important in the regulation of the collateral 
growth process (see below). One of the most important events of arteriogenesis is the recruitment 
and activation of monocytes at the site of remodeling (see below). Monocytes express VEGFR-1 
and VEGF can activate monocytes by binding this receptor, inducing chemotaxis
58
. 
 During femoral artery occlusion, angiogenesis does occur in the ischemic tissue and 
results in increased capillary bed density; this however does not bridge normoxic and ischemic 
regions of the organ.  Additionally, once hypoxia subsides, the increase in density is reversed
59
. 
Collateral vessels branching off downstream of the occlusion i.e. lacking a pressure gradient do 
not expand as much as those across the pressure gradient
61
. The mild increase in vessel diameter 
observed is possibly the result of arteriogenic factors released upstream. The primary increase in 
conductance after femoral artery ligation is observed in the circulation branching off proximal to 
the occlusion and distal to the ischemic tissue, spatial separating the growth process and 
hypoxia
60, 61




 Hemodynamic forces 
 Stenosis of a vessel results in a decrease in pressure downstream of the occlusion. This 
increases the pressure gradient across any other vessel perfusing the area. According to the 
13 
 
Hagen–Poiseuille equation, flow rate is directly proportional to pressure gradient (Eq. 1). The 
resultant increase in flow rate causes an increase in fluid shear stress at the vessel wall. Fluid 
shear stress at the vessel wall is the result of frictional forces between the flowing blood and the 
luminal surface of the endothelium (Eq. 2). Pressure also causes circumferential wall tension in 
the vessel wall, which is defined by the law of Laplace as the product of the pressure and the 
internal radius of the vessel divided by the thickness of the vessel wall (Eq. 3). This tension acts 




)     (Eq. 1) 
 
Shear stress (𝜏 =
4𝑄𝜇
𝜋𝑟3





)     (Eq. 3) 
 
Where ΔP is pressure gradient, τ= shear stress, 𝜎𝜃= circumferential stress, µ is dynamic viscosity,  
Q= Flow rate, L= length of vessel, r= internal radius of vessel, and t= vessel thickness. 
 
 A fundamental event in arteriogenesis is the mobilization and proliferation of SMCs. 
Located in the media, SMCs are physically shielded from changes in shear stress, and can only 
directly sense changes in circumferential wall tension or stretch. It is important to note that stretch 
is a function of absolute pressure and not pressure gradient, which increases due to a drop in 
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downstream pressure not an increase in pressure. However, increased flow has a vasodilatory 
effect, via increased NO production in the endothelium. Vasodilation causes an increase in 
internal radius and a decrease in wall thickness of the vessel. This leads to an increase in stretch. 
Stretch causes changes in the expression of several mediators and inhibitors of arteriogenesis. In 
cultured human smooth muscle cells and endothelial cells cyclic stretch causes an increase in 
monocyte chemo-attractant protein-1 (MCP-1)
63
, an important pro-arteriogenic factor
10
. In the 
rabbit aorta, stretch modulates the activation of focal adhesion kinase (FAK) in an integrin 
dependent  fashion that is unique from the effects induced by shear stress
67
. FAK is a key 
participant in integrin signaling which plays a central role in several processes of arteriogenesis.  
Stretch also causes an increase in VEGF in vascular SMC in lambs
64
. 
 The role shear stress plays in arteriogenesis is has been demonstrated in several studies. 
Ligation of intestinal arteries of rats results in a 2.5 fold increase in shear stress in the vessels 
collateral to the ligation. These vessels exhibit a significant increase in size one week after 
ligation
3
. Pipp et al demonstrate the role of increased fluid shear stress in arteriogenesis in pigs 
and rabbits by shunting the femoral artery post occlusion to the femoral vein, resulting in 2.3 fold 
increase in flow compared to the control that was occluded with no shunt. Collateral growth was 
2.4 fold higher in the shunted group compared to control
65
. Shear stress is a function of the third 
power or radius. As a result, it decreases precipitately as the vessel expands. Further emphasizing 
the role of shear stress, collateral growth halts at roughly 40% maximal conductance pre-
occlusion
53, 66
 artificially increasing shear stress by arteriovenous shunt resulted in rapid collateral 
growth and complete restoration of flow. Continued shunting caused further collateral growth that 
surpasses pre-occlusion conductance
72
.Individual infusion with several potent angiogenic growth 







 Mechanosensing and mechanotransduction  
 Although the exact mechanisms by which fluid shear stress is sensed and transduced are 
not entirely known, there are several candidates involved. Owing to the complex interactions and 
myriad of events orchestrated, it is highly unlikely that a single pathway is responsible for 
mechanotransduction. A reoccurring cast of soluble mediators and signaling pathways in both 
arteriogenesis and atherosclerosis implies a multi factorial mechanism, which may be tuned 
depending on the nature of endothelial fluid shear stress. Postulated contributors to fluid shear 
stress sensing include the glycocalyx, tyrosine kinase receptors, Ion channels, G protein receptors, 
integrins, adhesion molecules, cadherins, caveolae, and the cytoskeleton. 
 Ion channels expressed on the EC plasma membranes such as potassium, transient 
receptor potential (TRP) and chloride channels are activated by increased shear stress 
68-70
, 
causing changes in the polarization of the cell membrane. Shear stress also activates P2X4 
purinoreceptors, a member of the P2X purinoreceptors family of the ATP-gated cation channels 
77
, resulting in an influx of Calcium ions into the cell 
71
. P2X4 purinoreceptor activation is the 
result of endogenous ATP release 
72
 and is dose dependent on shear stress applied 
73
.  Knockout 
of P2X4 in mice results in diminished shear induced calcium influx
74
. Functionally these 
knockouts exhibited reduced NO production, hypertension, poor vasodilatation and impaired 
vascular remodeling. Suggesting a role for P2X4 purinoreceptors in the shear induced release of 
NO. The influx of calcium ions in response to shear stress has been demonstrated to originate in 
caveolae 
75
, where the shear induced release of ATP has also been shown to localize
76
.   
 Caveolae are 50 – 100 nm flask shaped invaginations of the plasma membrane. Caveolae 
contain a myriad of receptors, ion channels and protein kinases, all involved in signaling 
77
. They 
also contain large quantities of endothelial nitric oxide synthase (eNOS) which converts L-
arginine and oxygen to  L-citrulline and NO, under shear stress, caveolae release significant 
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amounts of NO 
78
. Caveolae are a form of lipid raft which are domains of the plasma membrane 
with increased concentration of cholesterol and sphingolipids. This results in increased order and 
decreased fluidity of the domain. In caveolae, multiple caveolin-1 molecules bind to cholesterol 
in these lipid rafts, they then form homo-oligomers, which further organize changing the structure 
of the lipid raft into a Caveolae. Caveolin-1 further binds filamin anchoring the caveolae to actin 
and the cytoskeleton
79
. In the endothelium of caveolin-1 knockout mice there is a complete 
absence of caveolae on the surface of the cell. Furthermore, these mice exhibit putative (eNOS) 
activity resulting in excessive vasodilation 
80, 81
. These mice also exhibited impaired vascular 
remodeling in response to chronically decreased flow
82
.   
 The endothelial glycocalyx consists of a layer of glycoproteins and proteoglycans 
localized to the luminal extracellular side of the vascular endothelial plasma membrane. 
Proteoglycans consist of a protein core bound to glycosaminoglycans (GAG). GAGs are variable 
length repeats of distinct disaccharides forming a linear heteropolysaccharide 
83
. These 
polysaccharides impart a highly negative charge to the proteoglycan that facilitates association 
with an array of cationic molecules circulating in the plasma 
84
. They achieve this high negativity 
by sulfation (an exception being hyaluronic acid which gains its charge from carboxyl groups
85
). 
Different disaccharide combinations and linkages result in different classes of GAGs. Common 
GAGs in the vasculature are heparin sulfate, chondroitin sulfate, dermatan sulfate and hyaluronic 
acid
86
. Heparin sulfate is the most common GAG in the endothelial glycocalyx constituting 50 – 
90% of all GAGs
87
. GAGs have been the subject of great focus due to their signaling abilities
88
. 
The thickness of the glycocalyx is highly sensitive to its environment, such as ion concentration 
and pH 
89, 90
. This is largely due to changes in the conformation of the coiled GAG chains in 
response to electrostatic interactions 
91
. Hyaluronic acid interweaves other GAG chains 
interacting with chondroitin sulfate and the hyaluronic acid receptor CD44 
92
 which is also 





 Hyaluronidase treatment of canine vessels prior to exposure to steady flow shear stress 
resulted in a 5 fold decrease in NO production compared to control 
94
. Treatment of cultured 
bovine aortic endothelial cells with heparinase III abolishes shear induced NO production 
95
. 
Interestingly, treatment with chondroitinase 
96
 has no significant effect on the shear induced NO 
production in Bovine aortic endothelial cells. The shear induced reorganization of the 
cytoskeleton in rat ECs exposed to shear stress in vitro is attenuated when the cells are cultured in 
serum free media 
97
, which results in the collapse of the glycocalyx. One possible mechanism of 
glycocalyx mechanotransduction is the outward extension of helical sulphonated GAGs. 
91
 This 
creates a form of dragline extended from the core protein. As shear stress increases it causes a 
conformational change in the coil exposing anionic moieties that bind sodium ions, this binding 
results in a conformational change of the protein core that conveys the shear signal to the 
cytoskeleton 
98
 where it can be transmitted to both cell-matrix and cell-cell adhesion points. 
 Cell-matrix adhesions are mostly mediated by integrins. Integrins’ mechanical role in cell 
adhesion coupled to their cell signaling capabilities suggest a possible role in 
mechanotransduction. Meyer et al. 
113
 used an activating antibody for integrin β and the integrin 
ligand RGD conjugated to ferromagnetic beads along with a magnetic twisting device to torque 
integrins to test their individual mechanotransductory potential in cultured bovine endothelial 
cells. Binding of the ligand or activating antibody resulted in a mild increase in cyclic adenosine 
monophosphate (cAMP). Upon application of shear stress the concentration of cAMP increased 
by three fold compared to control. They further demonstrated functional significance of this 
increase by quantifying the nuclear translocation of the catalytic subunit of protein kinase A 
(PKAc) and the activation of the transcription factor cAMP response element binding protein 
(CREB). Similar to cAMP, activation of integrin resulted in a small increase in nuclear PKAc. 
Applying torque to the integrins resulted in a dose dependent increase in nuclear PKAc up to 
threefold of control. The same pattern was observed with phosphorylation of CREB. This shear-
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induced increase in PKA signaling was attenuated after treatment with Guanosine 5′-[β-thio] 
diphosphate trilithium salt a general Gα inhibitor suggesting that integrins transduce mechanical 
signals through G-proteins. Ligand dependent activation of the integrin but not binding to actin 
filaments was also demonstrated to be necessary for the shear-induced increase in PKAc 
signaling. Suggesting that integrins-PKAc signal originates from the integrins and doesn’t require 
an external signal to be transmitted through the cytoskeleton. 
 Shear stress also results in ERK activation 
114
. This activation is inhibited by the 
transfection of a dominant negative mutant of FAK 
115
. Transfection with a dominant negative 
mutant of c-Src also inhibited the shear induced activation of ERK 
114
 this suggesting the 
involvement of integrins in the shear induced activation of the MAPK/ERK pathway. Integrins 
also activate TRPV4 channels when exposed to shear stress increasing calcium influx
99
.  
Furthermore, blocking of integrin binding to the ECM results in attenuation of the shear stress 
induced vasodilatation in porcine coronary arterioles 
117
. Shear stress has been shown to activate 
VEGFR-2 independent of its ligand
100
, this activation has been suggested to be integrin dependent 
and mediated by casitas b-lineage lymphoma (cbl) 
101
. Additionally, integrins mediate the 
stimulation of NF-κB leading to an increase in intercellular cell adhesion molecule-1 (ICAM-
1)
102
. Finally, activation of integrins by shear stress results in the reorganization of the endothelial 
cytoskeleton
103
. Integrins clearly play a role in mechanotransduction but the global effects 
integrin activation has on the cell, merits the discussion of other adhesion molecules connected to 
the cytoskeleton. 
 Several members of the immunoglobulin superfamily contribute to cell adhesion. The 
glycoprotein platelet endothelial cell adhesion molecule -1 (PECAM-1) is a member of the 
immunoglobulin superfamily with 6 immunoglobulin domains in its extracellular region. The 
cytoplasmic region of PECAM-1 is capable of binding the cytoskeleton by β-catenin and 
plakoglobin
104
. On the extracellular side PECAM-1 homophilically binds PECAM-1 on other 
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cells in a calcium independent manner. PECAM-1 lacks enzymatic activity but two tyrosines in 
the cytoplasmic region are phosphorylated when PECAM-1 is stimulated
105
. This usually 
involves the Src family of tyrosine kinases. The phosphotyrosines then bind Src homology 2 (SH-
2) domains on several intracellular signaling molecules. PECAM-1 is mostly expressed on the 
surface of endothelial cells, platelets and leukocytes. PECAM-1 is a negative regulator of 
leukocytes and platelets
106-109
. It also plays a role in the adhesion and migration of leukocytes. In 
the endothelium PECAM-1 is predominantly localized to cell-cell junctions. When bovine aortic 
endothelial cells are exposed to shear stress PECAM-1 is rapidly phosphorylated
110, 111
. SHP-2 
then binds the phosphorylated PECAM-1
112, 113
. GRB2-associated binding protein-1 ( Gab1) co-
localizes with PECAM-1/SHP-2
114
.  Gab1 is an adaptor protein interacts with SHP-2 to activate 
ERK
115
, suggesting a role for PECAM-1 in the shear induced activation of ERK. Indeed, Tzima et 
al. provide compelling evidence for the role of PECAM-1 as a mechanosensor within a larger 
mechanosensing complex. 
 While most cell-matrix adhesions consist of integrins, the cadherin family of adhesion 
molecules mediates most cell-cell adhesions. Cadherins are calcium dependent adhesion 
molecules. They are single pass transmembrane proteins, the N-terminal extracellular region of 
the protein contains tandem repeats of a motif called the cadherin domain. These 110 residue 
domains are rigid units, while the inter-domain areas are flexible. Calcium ions bind the inter 
domain regions significantly increasing their rigidity. This is the source of cadherin’s calcium 
dependence. There are 4 subfamilies of cadherins. Two subfamilies indirectly bind actin filaments 
at the cytoplasmic regions, these are the type I or “classical” cadherins which have 5 cadherin 
domain repeats the furthest of which has a conserved signal tryptophan. The type II cadherins are 
similar to type I, except for two conserved tryptophans on the distal cadherin domain. Also 
similar to type I cadherins are the desmosomal cadherins which bind intermediate filaments at the 
cytoplasmic regions. The final subfamily is the protocadherins which are further divided into 
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protocadherin α, protocadherin β, and protocadherin γ based on different cytoplasmic regions. 
These cadherins have variable length extracellular regions.  One of the type I cadherins is peculiar 
in that it consists of only an extra cellular region covalently bonded to GPI and is called T-
cadherin (truncated cadherin). Most cadherins are homophilic and generally only bind the same or 
a very similar cadherin on the cell surface of the opposing cell, this homophilic specificity is one 
of the mechanisms by which cells form homogenous tissues. Binding of cadherins occurs at the 
distal cadherin domain repeat where a knob and a pocket form which meets its counterpart from 
the opposing cell where the knob inserts into the pocket of the counterpart and vice versa.  
Cadherins are anchored to the cytoskeleton. Type I and II cadherins bind actin filaments through 
p120, β-catenin, and vinculin while desmosomal cadherins bind intermediate filaments through 
plakoglobin, plakophilin, and desmoplakin. These interactions with the cytoskeleton are essential 
to cadherins signaling capabilities. 
 In the vascular endothelium desmosomal cadherins are essential to maintain cell-cell 
adhesions. Furthermore, vascular endothelial (VE)-cadherin has been implicated in a signaling 
complex with VEGFR-2 and β-catenin mediates a shear stress induced activation of Akt
100
. 
Tzima et al. proposed an expansion of this complex to include PECAM-1
116
 and suggest it as a 
possible mechanism for the shear induced activation of integrins
116
. They report that in cultured 
endothelial cells exposed to flow both VE-cadherin null cells and PECAM-1 null cells show 
diminished activation of integrins. It was also demonstrated that VE-cadherin was necessary for 
the flow-induced increase in phosphatidylinositol 3 kinase (PI3K) activity, and that PECAM-1 
was required for the increase in both PI3K and Src following shear stress. They further 
demonstrated that VE-cadherin activation of PI3k was ligand independent and mediated by 
VEGFR-2. Finally, they also showed that the direct application of shear stress to PECAM-1 
causes the ligand independent activation of VEGFR-2 via Src and is dependent on VE cadherin.   
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  One proposed model of the cytoskeleton that facilitates the conduction of mechanical 
forces across the cell is the tensegrity model proposed by Donald Ingber
117
. Tensegrity is an 
architectural principle for the design of bodies that are in constant tension in such a way that 
endows integrity, thus the name: tensegrity. The core concept of tensegrity is three or more non-
touching rods or struts under constant compression bound together by pre-stressed tendons that 
define the body spatially. Tensegrity structures are geodesic because the tensioned tendons take 
the shortest path between on node and another making them the optimal geometry for baring that 
specific load.  Furthermore, free standing tensegrity structures will rearrange while maintaining 
compression and tension when exposed to changes in mechanical forces to maintain optimal load 
bearing. In the cell model suggests microtubules as the compression struts, while actin and 
intermediate filaments act as tendons to form the cellular tensegrity.   
 Inflammation and arteriogenesis 
 The inflammatory nature of arteriogenesis is outlined by the upregulation of several 
inflammatory mediators in vessels after increased shear stress. These include adhesion molecules 
such as E- and P-selectins, intercellular ICAM-1 and vascular cell adhesion molecule (VCAM-
1)
133-136
 and the chemokines such as MCP-1, CCL3, and CCL7 
118
. These molecules play an 
important role in the recruitment and activation of leukocytes (in particular monocytes). Rabbits 
treated with MCP-1 exhibit increased femoral collateral growth after femoral artery occlusion 
compared to untreated controls
119
 this increase was attenuated by blocking ICAM-1
120
 suggesting 
that monocyte adhesion is required for the observed increase. Mice lacking MCP-1 expression 
show diminished collateral growth in response to femoral artery ligation
121
. Surprisingly, Mice 
lacking the receptor for MCP-1 (CCR2) have been reported to exhibit both normal and 





 Evidence for the role of monocytes in arteriogenesis was demonstrated in osteopetrotic 
mice with significantly diminished monocytes
8
. These mice exhibited significantly decreased 
restoration of perfusion compare to controls.  Monocytopenia induced in mice using 5-
fluorouracil (5-FU) also leads to reduced restoration of flow
124
. Conversely, increased monocytes 
due to rebound from 5-FUtreatment or supplement increased percentage of restored flow
124
. 
Interestingly, neutrophils are reported to also invade the collaterals early in the remodeling 
process 
142
. This early neutrophil population may serve to prepare the tissue for monocyte 
invasion 
143
.  Monocytes exact an arteriogenic effect by releasing growth factors and cytokines 
such as interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and basic fibroblast growth 
factor (bFGF)
144,145
.  IL-1β induces a phenotypic shift of SMCs from contractile to inflammatory 
mediated by NF-κB 
146
 which is a necessary event in the remodeling process. TNF-α on the other 
hand induces SMC migration 
147
. TNF-α knockout mice exhibit significantly decreased flow 
restoration after femoral artery occlusion compared to control 
125
. bFGF is a mitogen for both 
endothelial and smooth muscle cells
126
. bFGF infusion of rats with femoral artery occlusion 
resulted in increased restoration of flow to the calf muscle compared to placebo control 
127
. bFGF 
gene treatment significantly improved cardiac function during chronic myocardial ischemia in 
pigs
128
. This was accompanied by a significant 3.4 fold increase in vessel thickness compared to 
control. Furthermore, in a canine model for ischemic heart disease intracoronary administration of 
bFGF induced a 40% increase in collateral flow compared to control after surgical occlusion of 
the left circumflex coronary artery
126
. This increase was demonstrated to have a spatial and 
temporal component as neither intravenous nor pericardial administration affected collateral flow. 
Single administration of bFGF on the first day of occlusion had no effect on collateral flow 
129
. 
This correlates with the appearance of monocytes in the collaterals 24 hours after occlusion
153
. In 
SMCs bFGF causes an increase in ERK1/2 phosphorylation mediated by MEK that results in an 
increase in the expression of the transcription factor early growth response-1 (Egr-1) 
130
. Egr-1 
promotes cell survival and proliferation 
155,156





by mechanical stress 
131
 including shear stress 
159
. Egr-1 induces the expression of platelet-derived 
growth factor  
160,161
 and insulin like growth factor-2 (IGF-2) 
162
.  Egr-1 knockout rats 
demonstrate diminished collateral development compared to controls after femoral excision. 
Inversely, adenoviral induced over expression of egr-1 resulted in increased collateral 
development after femoral excision 
132
. In the mouse adenoviral over expression of egr-1 resulted 
in increased restoration after femoral ligation 
133
. Egr-1 also regulates the expression of 
Transforming growth factor-β1 (TGF- β1) 
165
 which has been shown to upregulate the expression 
of FGFR-1 
134
 which, has been proposed has the rate limiting step in bFGF signaling 
134
. 
 Granulocyte-macrophage colony stimulating factor (GM-CSF) stimulates the 
differentiation of hematopoietic stem cells into monocytes, which play a key role in 
arteriogenesis. Increased shear stress causes a dose dependent increase in GM-CSF expression in 
cultured ECs
135
.  GM-CSF causes an increase in the expression of the pro-arteriogenic factors 
MCP-1 and MMP12 in macrophages
136
. GM-CSF treatment after femoral artery ligation in 
rabbits increases macrophage recruitment to growing collaterals, flow restoration, and collateral 
vessel size
136, 137
. GM-CSF had a synergistic effect with MCP-1 increasing flow restoration 
beyond either factor on its own
138
. These findings suggest GM-CSF may be a candidate pro-
arteriogenic factor released by the endothelium to increase monocyte recruitment. In a rat model 
for stroke GM-CSF significantly increased the size of the posterior cerebral artery after ligation of 




. GM-CSF had the same effect in mice after 









 Nitric oxide  
 Nitric oxide (NO) is a soluble gaseous free radical produced by the nitric oxide synthase 
(NOS) family of proteins. NO plays an important role as a messenger in several physiological 
situations and is used as a cytotoxic agent by macrophages during inflammation. In the 
vasculature shear stress increases the production of NO by endothelial NOS (eNOS) in ECs. NO 
diffuses into SMCs, where it increases the activity of guanylate cyclase increasing the secondary 
messenger cGMP which in turn activates PKG which phosphorylates several downstream 
proteins resulting in SMC relaxation and vasodilatation. Inducing an increase in NO production 
by L-arginine dietary supplementation resulted in an increase in flow restoration after femoral 
artery excision in rabbits
141
. eNOS knockout mice on the other hand, exhibited diminished flow 
recovery after femoral artery excision
141
. In the dog myocardium repeated occlusion of the left 
anterior descending coronary artery resulted in growth of the coronary collaterals
142
. This growth 
was attenuated by the administration of L-NG-nitroarginine methyl ester (L-NAME) a 
nonspecific inhibitor of NOS. The arteriogenic effects of bFGF in rats after femoral artery 
ligation were reduced to vehicle control levels after L-NAME treatment
143
. eNOS is localized to 
the endothelium which experiences a six fold increase in expression
144
. Exercise accelerates 
arteriogenesis after femoral ligation and further increases eNOS expression
5
.  L-NAME also 
inhibited collateral growth augmentation by exercise after femoral artery ligation in rats
145
. 
Interestingly, L-NAME did not inhibit exercise induced angiogenesis
145
. These varying effects of 
NO on arteriogenesis and angiogenesis were further demonstrated in rats overexpressing eNOS 
by adenoviral transfection. After femoral artery ligation, rats overexpressing eNOS exhibited 
increased collateral size and flow restoration but normal capillary density compared to control
146
.  
As stated earlier, eNOS knockout mice exhibit diminished arteriogenesis after femoral artery 
occlusion
141
.  However, collateral growth was demonstrated to “catch up” with wild type mice 
later in the arteriogenic process
146
. Mice were treated with L-NAME either immediately after 
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femoral artery ligation or 3 days post-surgery. Both groups showed significant decreases in flow 
recovery compared to control
147
, emphasizing the importance of NO during the entirety of 
arteriogenesis. Inhibition of inducible NOS (iNOS) in eNOS knockout mice resulting in severely 
decreased collateral growth after femoral artery ligation compared to control
148
 suggesting a 
transition from eNOS to iNOS dependent NO production as arteriogenesis progresses.   
 PLGF 
 In 1991 Maglione et al. described the cloning of a 877 kb cDNA segment isolated from 
human placenta coding for a 149 residue protein. They demonstrated that this protein is a N-
glycosylated secreted dimeric protein covalently bonded by disulfide bonds. The protein also 
exhibited strong sequence similarity (53%) to vascular endothelial growth factor (VEGF), and 
was aptly named placental growth factor (PLGF)
149
. The human PLGF gene is located on 
chromosome 14q24
150
. Alternative splicing of PLGF’s seven exons results in four different 
isoforms, PLGF 1–4
150-153
. An insertion of 21 basic amino acids in PLGF-2 and PLGF-4 acts as a 
heparin-binding domain. PLGF-1 and PLGF-3 lack this domain
150, 151, 153
. This highly basic 
insertion also allows PLGF-2 to bind to neuropilin-1 and -2
154
.  
 X–ray crystallography revealed that PLGF consists of two α-helices and seven β-sheets. 
Two disulfide bonds form between four cysteine residues on β3 and β7 to form a ring which is 
penetrated by a disulfide bond between two cysteines on β1 and β4
155
. The resultant structure is 
known as a cysteine knot motif
156
. Two more cysteines form two disulfide bonds with two 
cysteines on another symmetrically opposite PLGF monomer to form a dimer
155
. PLGF 






 along with 
VEGFR-3
193
 form the VEGF receptor family which are a member of type III tyrosine kinases. 
They consists of a seven immunoglobulin domain extra cellular segment
158
, a single 
transmembrane domain, and a cytoplasmic tyrosine kinase segment containing a kinase insert 
domain
40





, while domains 2 and 3 of the extracellular immunoglobulin domains are responsible 
for binding on the receptor
160
. Like other tyrosine kinase receptors, only one monomer of the 
PLGF dimer binds VEGFR-1 while the second monomer binds a second VEGFR-1 molecule 
resulting in a VEGFR-1 dimer
160
. The juxtaposed tyrosine kinase domains on each receptor then 
transphosphorylate tyrosine residues on the opposite receptor
161
. The phosphotyrosines act as 








 are also 
capable of binding VEGFR-1. Initially, PLGF was thought to only act by releasing VEGF from 
VEGFR-1, which in turn would activate VEGFR-2. This was due to the weak kinase activity of 
VEGFR-1. Knockout of the VEGFR-1 receptor resulted in poor survival due to disorganized 
embryonic vasculature
164
 but mice expressing a mutant VEGFR-1 with inactive kinase showed 
normal development
201
. This suggested that VEGFR-1 acts as a decoy receptor for VEGF. Since 
then, PLGF has been shown to exact effects independent of VEGF and VEGFR-2 via multiple 
signaling pathways. PLGF activates the mitogen activated protein kinase (MAPK) pathway in a 
VEGFR-1 mediated fashion in multiple cancerous cell lines
165-167
. Monocytes predominantly 
expressing VEGFR-1 are activated by PLGF despite no VEGFR-2 receptors present
168
. Inhibitors 
of MAPK kinase (MEK) and phosphoinositide 3′ kinase (PI3K) abrogate the effects of PLGF on 
monocytes
169
. PLGF signaling in smooth muscle cells involves Janus kinase (JAK) and Signal 
Transducer and Activator of Transcription III (STAT3) to induce proliferation
170
. The 
involvement of these signal pathways outlines PLGF’s role in cell survival and proliferation. 
Furthermore, PLGF binding to VEGFR-1 results in a distinctive pattern of transphosphorylation 
compared to VEGF implying different downstream effects
171
. Indeed, analysis of microarray data 
collected from human umbilical vein endothelial cells shows treatment with PLGF or VEGF-A 
induce distinctive transcription patterns that are non-overlapping
172
. Additionally, VEGFR-1 
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activation by PLGF leads to crosstalk between VEGFR-1 and VEGFR-2 that amplifies VEGFR-
2’s downstream signal 
171
 ultimately leading to enhanced VEGF signaling
4
. 
 Arguments against VEGFR-1 signaling are the result of a VEGFR-1 selective VEGF 
mutant failing to elicit a mitogenic effect or significantly activate extracellular signal-regulated 
kinase (ERK 1/2) or PI3K
173




 PLGF naturally dimerizes with VEGF in cells expressing both growth factors
174
. Due to 
the inability of PLGF to bind VEGFR-2 the VEGF/PLGF heterodimer is capable of dimerizing 
VEGFR-1 with VEGFR-1 or VEGFR-2 but not VEGFR-2 with VEGFR-2 
175
. The mitogenic 
effects of this heterodimer are a point of controversy in the literature. The VEGF/PLGF 
heterodimer exhibits a ~30 fold decrease in mitogenic effect compared to VEGF in endothelial 
cells
176
. Studies reporting angiostatic effects of the heterodimer attribute it to a decrease in the 
amount VEGF available to form homodimers
177-179
. Tarallo et al. demonstrate that the 
heterodimer exhibits decreased angiogenesis in favor of arteriogenesis (as indicated by decreased 
sprouting and increased caliber of vessels)
175
, these effects are attenuated when a non VEGFR-1 
binding PLGF mutant is used inhibiting any receptor dimerization
175
. Indeed, the studies in ref.  




 During pregnancy, a pathological condition called preeclampsia may develop which is 
marked by maternal endothelial dysfunction, hypertension, proteinuria, and hepatic and renal 
damage. One hypothesis suggests that insufficient placental perfusion causes the placenta to 
release vasoactive mediators that cause the endothelial dysfunction
218
. Maynard et al. found a 4-
fold increase in soluble VEGFR-1 (sVEGFR-1) in patients presenting preeclampsia compared to 
control patients
181
. sVEGFR-1 is a secreted non-membrane bound isoform of VEGFR-1, and acts 
as a competing receptor
220





. PLGF plays an important role in preeclampsia. Decreased urinary PLGF is associated 
with preeclampsia and is suggested as a possible predictive marker of the condition
182
. PLGF 
induces the vasodilatation of uterine arteries of rats
183
. Mice over expressing sVEGFR-1 by 




 The vasculature of neoplasms and its extensiveness is directly related to patient survival 
218,224
. Overexpression of PLGF results in increased perfusion and growth of implanted tumors in 
mice
225,226
. This effect is in part due to increased survival and proliferation of both ECs and 
macrophages
225,226
, whereas knockout of the VEGFR-1 receptor on monocytes attenuates the 
effects of PLGF overexpression 
227
. Conversely, inhibition of PLGF by antibodies results in 
diminished perfusion and growth of tumors from several origins 
185, 186
. PLGF antibodies inhibit 
tumor growth by suppressing the expansion of arterioles rather than affecting the capillary 
network 
186
. PLGF also directly affects neoplastic cells increasing motility and invasion of breast 
cancer cells 
167, 187
. PLGF increases the growth of acute lymphoblastic leukemia cells
188
. These 
effects of PLGF are mediated by increased ERK1/2 phosphorylation 
187, 189
. 
 Most of PLGF’s roles in disease are the result of its effects on blood vessels. 
Interestingly, PLGF knockout in mice is non-lethal and embryos develop normally
4
. These mice 
however, exhibit poor arteriogenesis after femoral ligation 
4
. PLGF treatment improves the poor 
arteriogenesis
10
. While treatment of wild type mice with PLGF after femoral ligation improved 
flow, restoration 3 fold compared to control
11
. Transgenic mice overexpressing PLGF exhibit 
enlarged, tortuous vessels, with increased density and branching 
6
. These studies support PLGFs 
role an arteriogenic factor. The effects of PLGF are monocyte dependent. After femoral ligation 
in rabbits, treatment with PLGF resulted in a significant increase in femoral collateral growth 
compared to control or VEGF-E treatment
10
. This growth however is attenuated in rabbits 
depleted of monocytes
10
. Emphasizing the role of bone marrow derived cells in PLGF mediated 
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arteriogenesis, wild type bone marrow transplantation into PLGF knockout mice ameliorates poor 
arteriogenesis
9
. Concurrent treatment of mice after femoral artery ligation with PLGF and VEGF 
resulted in greater collateral growth than either PLGF or VEGF on their own
190
. In agreement 
with these findings, PLGF enhances the effects of VEGF on ECs and is necessary for VEGF 
induced SMC proliferation
191, 192
. PLGF also decreases VEGF induced endothelium permeability 
by increases adherens junctions 
193
. In rats, direct injection of PLGF in to coronary arteries 
improved cardiac function and a thicker myocardium in the penumbra after left anterior 
descending artery ligation compared to vehicle control 
241
. Similarly, adenoviral transfection of 
PLGF after ligation of the left anterior descending coronary in mice resulted in enlargement of 
coronary vessel accompanied by improved cardiac function compared to control
194
. 
 Effects of disease on arteriogenesis 
 Before pharmacological stimulation of arteriogenesis by any agent is considered it is 
important to understand the pathological context within which it must act. Metabolic syndrome 
and type II diabetes mellitus are more prevalent in patients with poor coronary collateral 
development after coronary obstruction compared to patients with good coronary collateral 
development
195
. Metabolic syndrome consists of a group of symptoms that are detrimental to 
cardiovascular health. These include hypertension, dyslipidemia, central obesity and insulin 
resistance 
244,245
. Based on multivariate analysis, hyperglycemia is statistically the most 
detrimental risk factor to collateral growth
196
. The endothelium of hyperglycemic patients is 
dysfunctional. The increased circulating glucose leads to protein glycation (non-enzymatic 
glycosylation of proteins at arginine and lysine residues) resulting in advanced glycation end 
products (AGE). During the process, hydrogen peroxide is released, increasing oxidative stress. 
The AGEs themselves accumulate in the basement membrane of the vascular endothelium, where 
they contribute to endothelial dysfunction. Hyperglycemia diminished collateral growth in the 





myocardial ischemia was induced by repetitive coronary occlusion in obese (but not insulin 
resistant) rats. These rats showed no coronary growth, in contrast to their lean littermates that 
achieved 81% flow restoration 
248
. In the obese rats, treatment with VEGF failed to improve 
collateral growth. However, concurrent treatment with VEGF and superoxide dismutase (SOD, an 
enzyme that breaks down superoxide to oxygen and hydrogen peroxide, which is further broken 
down by catalase) resulted in a significant increase in flow restoration
248
. Similarly, treatment 
with antioxidants resulted in improved collateral growth in the same model 
249
. Knockout of SOD 
in mice results in impaired femoral collateral growth and flow recovery after femoral artery 
ligation compared to control. These animals also exhibited diminished bone marrow derived cells 
in the collateral area 
198
. NADPH oxidase is an enzyme complex that catalyzes the formation of 
superoxide. gp91
phox
 is a subunit of NAPH oxidase which along with p22
phox
 is responsible for 
production of superoxide. gp91
phox
 deficient mice were treated with streptozotocin (STZ) (a toxin 
with enhanced cytotoxicity towards beta cells) to simulate type I diabetes mellitus. After femoral 
ligation, collateral growth was increased in these animals compared to wild type STZ treated 
mice and comparable to wild type untreated, suggesting superoxide is an anti-arteriogenic factor 
199
. However, poor femoral collateral growth was reported in untreated gp91
phox
 knockout mice 
compared to wild type after femoral artery ligation
200
. This dual effect was further investigated in 
rat treated with either diphenyleneiodonium, an inhibitor of NADPH oxidase, or 
diethyldithiocarbamate, an inhibitor of SOD. Surprisingly, both treatments resulted in decreased 
coronary collateral growth after repetitive occlusion. Furthermore, p38 MAP kinase was 
demonstrated to be activated by repetitive occlusion, and this effect was diminished by either 
treatment
201
. The authors proposed that there is a narrow range within which oxidative stress is 
pro-arteriogenic, and that deviations in either direction reduce collateral growth. However, 
another conclusion could be drawn, considering the nature of the treatments used in the study 
above. Both treatments, despite attempting to increase or decrease oxidative stress, cause a 
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decrease in H2O2. The pro-arteriogenic factor PLGF is up regulated by H2O2 in SMCs 
202
. 
Similarly, Egr-1 expression is increased after H2O2 treatment 
255,256
. 
 Patients with advanced diabetes mellitus exhibited decreased peripheral vasodilation after 
either heating the limb or administration of sodium nitroprusside
203
. These patients also exhibited 
reduced eNOS expression. Similarly, eNOS mRNA and protein are significantly decreased in the 
endothelium of a rat model of type I diabetes compared to wild type control 
204
. Treating mice 
with STZ resulted in a decrease in NO production, and was demonstrated to be the result of 
decreased Akt expression
205
.  Interestingly, type I diabetic mice have decreased eNOS expression 
compared to type II diabetic mice, and both models were less than control
206
. Femoral artery 
ligation caused no change in eNOS expression in type I diabetic mice, but resulted in a drop in 
eNOS expression in Type II diabetic mice to type I diabetic levels 
206
, suggesting that although 
differences between the type of diabetes and endothelial dysfunction exist, they are equally 
impaired with regard to arteriogenesis. 
 Monocytes play an important part in arteriogenesis. Several studies demonstrate that 
monocyte recruitment in diabetes mellitus is impaired, and that pharmacologically increasing 
monocyte recruitment could improve arteriogenesis. Diabetic patients with critical limb ischemia 
were treated with recombinant GM-CSF, which resulted in improved perfusion of the ischemic 
limb compared to placebo control. This was accompanied with a tenfold increase in bone marrow 
derived cells
207
. Rabbits treated with the cytotoxic glucose analogue alloxan to simulate type I 
diabetes exhibit diminished flow restoration following femoral artery ligation. Monocytes from 
the alloxan treated mice demonstrated reduced motility when treated with VEGF-A or MCP-1
208
. 
Monocytes from diabetic patients likewise exhibit reduced VEGFR-1 mediated motility 
compared to control. This effect however was not due to decreased ligand binding or tyrosine 
kinase activity
209
; diabetic patients were also found to express significantly less VEGFR-1 in the 
myocardium, compared to non-diabetic patients
210
. Furthermore, diabetic patient monocytes 
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exhibit increased baseline phosphorylation of signaling proteins downstream of VEGFR-1 such 
as Akt, MAPK P38, and ERK1/2
211
. These monocytes also exhibit increased expression of the 
AGE receptor
212
. Furthermore, high concentrations of glucose cause cultured ECs to significantly 
increase MCP-1 expression
213
. One possibility for reduced monocyte activation is that the 
increased inflammatory state in diabetes mellitus “drowns out” the pro-arteriogenic signal 
mediated by VEGFR-1 or other pathways. 
 The remodeling of the ECM is absolutely necessary for the progression of arteriogenesis. 
The effects of diabetes mellitus on the vascular ECM are largely unknown, although some studies 
have focused on this topic. Mice treated with STZ exhibited poor femoral collateral growth after 
femoral ligation compared to untreated controls. This diminished growth was improved by 
treatment with aminoguanidine, which inhibits AGE formation 
214
. Interestingly, these mice 
showed no change in MMP-2, MMP-3 or MMP-13 expression. However, MMPs are expressed as 
zymogens, and STZ treated mice did exhibit decreased protease activity, which was again 
improved by aminoguanidine treatment 
214
. Similarly, a mouse model for type II diabetes mellitus 
arising from spontaneous mutation of the leptin receptor exhibited reduced MMP-2, MMP-12 and 
MMP-16 mRNA, compared to wild type control
215
.  In contrast, mice treated with STZ were 
found to express excessive MMP-2 and MMP-9 and reduced TIMP-1 after femoral artery 
excision compared to control 
216
. However, no data were provided in that study regarding the 
functionality of these increased MMPs. These studies suggest that ECM remodeling via MMPs is 
impaired during diabetes mellitus, although further investigation is needed to understand the 
mechanisms of this inhibition. 
 Inward remodeling vs. outward remodeling 
 Atherogenesis and arteriogenesis show several similarities, and a real risk of stimulating 
arteriogenesis is aggravating pre-existing plaque or driving the formation of new plaque. This is 
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in part due to the dual effects many arteriogenic factors have. An understanding of how these 
similar growth factors and cytokines are coordinated to produce either lifesaving remodeling or 
lethal pathology is essential for the development of safe and effective pro-arteriogenic therapies. 
 A key event in both arteriogenesis and atherosclerosis is a phenotypic shift of SMCs, 
along with SMC migration and proliferation. FGF2 stimulates SMC growth and is necessary for 
arteriogenesis. Acidic fibroblast growth factor (FGF1) also shows arteriogenic potential. 
Prolonged delivery of FGF1 to ischemic porcine hearts caused an increase in cardiac function and 
greater perfusion of the ischemic zone
27
. Intra-arterial transfection with the FGF1 gene following 
femoral artery ligation resulted in increased collateral development in rabbits
217
. FGF1 and FGF2 
also exhibit pro-atherosclerotic effects. Both growth factors’ expression is increased in human 
atherosclerotic lesions and in restenotic lesions
218
. Rats treated with bFGF after carotid artery 
denudation exhibited a 2.4-fold increase in intimal hyperplasia
219
, while transfection of porcine 
arteries with the aFGF gene leads to intimal hyperplasia
220
.  The role of inflammation in both 
arteriogenesis and atherosclerosis is well established
274,275
. Essential for the progression of both 
remodeling processes is the recruitment of monocytes. Flow restoration was significantly 
improved with MCP-1 treatment after femoral artery ligation in minipigs
221
. Nicotine treatment 
increases the restoration of flow after femoral artery occlusion in rabbits. This increase is 
comparable to that found with FGF2 treatment. Furthermore, nicotine causes upregulation of 
ICAM-1 and MCP-1 expression in endothelial cells, while increasing CD11a and CD11b 
expression in monocytes.  As expected, an increase in monocyte adhesion and migration is also 
observed
222
. Human atherosclerotic lesions stain positive for MCP-1
223
. Hyperlipidemic mice 
were treated with nicotine via drinking water for 20 weeks. This resulted in a marked increase of 
atherosclerotic lesion size
224
. The role of PLGF in arteriogenesis has been extensively studied and 
PLGF has even been suggested as possible treatment for ischemic heart disease. This however, 
must be weighed against the finding that in patients exhibiting multi-vessel coronary 
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atherosclerotic lesions, a reduction in circulating sVEGFR-1 was observed compared to patients 
with a single lesion or no lesions
225
. This reduction would most likely lead to increased PLGF 
bioavailability. Indeed, adenovirally induced overexpression of PLGF increased intimal 
thickening in both high cholesterol- and normal diet-fed rabbits compared to control
281
, while 
PLGF knockout in hyperlipidemic mice resulted in diminished plaque area and macrophage 
content compared to hyperlipidemic mice normally expressing PLGF
281
. These results were 
repeated when hyperlipidemic mice were treated with PLGF antibodies
282
. Interestingly, this dual 
effect is also observed for endogenous angiogenesis inhibitors such as endostatin, which 
demonstrates both anti-arteriogenic
226
 and anti-atherogenic 
284
 effects.  This athero/arteriogenic 
relationship extends further than single mediators to whole animals. Two commonly used mouse 
strains are C57BL/6 and Balb/c. These two strains display different degrees of response to 
femoral artery ligation. Limbs of C57BL/6 mice are briefly hypoxic, but arteriogenesis progresses 
rapidly after ligation. In contrast, Balb/c mice develop severe limb hypoxia, and flow recovery 
time is increased compared to C57BL/6 mice. On the other hand, Balb/c mice resist diet-induced 
atherosclerosis, while C57BL/6 mice are susceptible to diet-induced atherosclerosis. Mice express 
high-density lipoprotein (HDL) as their predominant lipoprotein
227
. HDL reduces monocyte 
recruitment 
285
. C57BL/6 mice express lower HDL than Balb/c mice
228
, which may be a possible 
explanation for the strain differences observed. In a more clinical aspect, the degree of coronary 
collateral development assessed by angiography is positively correlated with the development of 
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Placental growth factor (PLGF), a potent stimulator of arteriogenesis, is upregulated 
during outward remodeling. Increased fluid shear stress (FSS) is a key physiological stimulus for 
arteriogenesis. However, the role of FSS in regulating PLGF expression is unknown. To test the 
hypothesis that fluid FSS can regulate PLGF expression in vascular cells, and to identify 
signaling pathways involved, human coronary artery endothelial (HCAEC) and smooth muscle 
(HCASMC) cells were cultured on either side of porous Transwell inserts. HCAEC were then 
exposed to pulsatile FSS of 0.07 Pa ("normal," mimicking flow through quiescent collaterals), 
1.24 Pa ("high," mimicking increased flow in remodeling collaterals) or 0.00 Pa ("static") for 2 h. 
High FSS increased secreted PLGF protein ~1.4-fold compared to static control (n=5, p<0.01), 
while normal FSS had no significant effect on PLGF. Similarly, high flow stimulated PLGF 
mRNA expression ~2-fold in isolated mouse mesenteric arterioles. PLGF knockdown using 
siRNA revealed that HCAEC were the primary source of PLGF in cocultures (n=5, p<0.01). Both 
H2O2 and NO production were increased by FSS, compared to static control (n=5, p<0.05). L-
NG-nitroarginine methyl ester (100 µM) had no significant effect on the FSS induced increase in 
PLGF. In contrast, both catalase (500 U/mL) and diphenyleneiodonium (DPI, 5 µM) attenuated 
the effects of FSS on PLGF protein in cocultures. DPI also blocked the effect of high flow to 
upregulate PLGF mRNA in isolated arterioles. Further studies identified Nox4 as a source of 
ROS for this pathway. We conclude that fluid FSS regulates PLGF expression, and that this 
regulation is dependent on Nox4 and ROS signaling. 
 Keywords: arteriogenesis, collateral circulation, hemodynamics, endothelium, vascular 
endothelial growth factors 
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New and Noteworthy  
Here we provide the first direct demonstration that the arteriogenic mediator placental 
growth factor (PLGF) is regulated by elevated fluid shear stress (a physiological stimulus for 
collateral artery remodeling) in both vascular cell cocultures and isolated perfused arterioles. We 
further identify Nox4 and H2O2 as downstream mediators of this response. 
 
Introduction 
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in both 
western and developing countries, and even optimistic projections predict it to remain so for the 
foreseeable future. Coronary artery disease is characterized by stenosis of the coronary arteries 
due to atherosclerosis, resulting in decreased perfusion of downstream tissue. The decreased 
pressure downstream of the occlusion drives blood through small preexisting collateral vessels 
that bridge the area of low pressure with areas of higher pressure. With time, these collateral 
vessels remodel outward, increasing their conductive capacity and the perfusion of the ischemic 
tissue in a process called arteriogenesis. In CAD patients, the degree of collateral development 
correlates directly with positive outcome
130
. Unfortunately, collateral development is highly 
variable in humans
230
. Thus, new pharmacological interventions to induce arteriogenesis could 
prove life-saving for those CAD patients who have limited native ability to remodel collaterals. 
However, attempts to induce arteriogenesis by administration of growth factors such as VEGF-A 
have yielded disappointing results, indicating that a better understanding  of the mechanistic basis 
of arteriogenesis is needed
231, 232
. 
Increased flow demand on collateral vessels downstream of arterial stenosis or occlusion 
results in an increase in fluid shear stress (FSS) on the arterial wall. The role of FSS as a key 
initiating stimulus for collateral remodeling has been extensively demonstrated
3, 65, 233, 234
. FSS is 
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inversely proportional to the cube of vessel diameter, and rapidly decreases as the vessel wall 
expands. However, prolonged increased FSS achieved by arteriovenous shunt results in continued 
enlargement of collateral vessels
65, 67, 235, 236
. Recently, compelling clinical evidence for the role of 
FSS in arteriogenesis was provided by Gloekler et al
237
. Diastolic coronary flow was 
pharmacologically increased in patients with CAD for six months, resulting in a significant 
increase in coronary flow index (CFI) compared to placebo control. The treatment group also 




Placental growth factor (PLGF) is a member of the vascular endothelial growth factor 
(VEGF) family. PLGF is a potent stimulator of collateral growth, inducing more collateral vessels 
and greater flow recovery in mouse and rabbit hindlimb after femoral artery ligation than VEGF-
A
10, 11
. Evidence from PLGF
-/-
 mice suggests that PLGF is required for normal collateral 
remodeling, as re-establishment of hindlimb perfusion after femoral artery ligation is severely 
delayed in these mice
4
. On the other hand, overexpression of PLGF causes a marked increase in 
vessel size
6
 and increased resistance to myocardial infarction
194, 225
 in mice. Clinically, higher 
levels of PLGF predict improved patient outcome following acute myocardial infarction, as 
demonstrated by increased  left ventricular ejection fraction
238
.  
The mechanism by which PLGF stimulates collateral remodeling is thought to rely on 
recruitment of monocytes to the vessel wall. These monocytes in turn orchestrate the remodeling 
process
239
. Although some insights have been gained into the downstream effects of PLGF as 
mediated by monocytes, the mechanisms regulating PLGF expression in the vessel wall during 
collateral remodeling remain largely unknown. The importance of both PLGF and FSS in 
collateral remodeling led us to hypothesize that FSS may regulate the expression of PLGF in the 
vessel wall. This hypothesis is supported by our previous observation that PLGF mRNA 
expression is sharply increased in hindlimb collateral arterioles of both sedentary and exercise-
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trained rats immediately following acute femoral artery ligation, then decreases gradually as 
remodeling progresses
5
. Resting blood flow was sufficient to support tissue metabolic needs in 
sedentary but not exercising rats, yet PLGF was upregulated similarly in both groups, suggesting 
that elevated FSS can upregulate PLGF even in the absence of tissue hypoxia. The present study 
used an in vitro endothelial cell/smooth muscle cell coculture (EC/SMC) model of the vessel wall 
and isolated perfused mouse mesenteric arterioles to directly characterize the effects of FSS on 




 Reagents. All reagents were purchased from Sigma-Aldrich unless otherwise specified. 
 
Perfused arterioles. All animal experimental procedures were approved by the 
Institutional Animal Care and Use Committee at Oklahoma State University. Experiments were 
conducted on isolated second order mesenteric arterioles (≈120-180 μm) of 6-8 week-old 
C57BL/6J male mice (Jackson Laboratories). Mice were anesthetized with isoflurane delivered 
by a vaporizer and the heart was excised. The entire mesentery with the superior mesenteric 
artery and vein was dissected and washed with 4 ºC PBS. Second order mesenteric arterioles were 
isolated from the mesenteric tissue. The isolated artery was transferred to a vessel chamber at 4ºC 
(Living Systems Instrumentation). The chamber contained a pair of glass micropipettes and was 
filled with physiological saline solution (PSS; 142 mM NaCl, 4.7 mM KCl, 1.7 mM MgSO4, 0.5 
mM EDTA, 2.79 mM CaCl2, 10 mM HEPES, 1.18 mM KH2PO4, pH 7.4). After cannulation of 
the proximal (upstream) end of the vessel, the intraluminal pressure was gradually raised (less 
than 20 mmHg) to clear the lumen of clotted blood. Once cleared, the distal (downstream) end of 
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the vessel was also cannulated. Time from euthanasia to complete cannulation was under 60 
minutes. The temperature of the bath was then raised to 37ºC and pressure was gradually raised to 
60 mmHg (~10 mmHg/10 minutes). The pressure increase was achieved by gradually raising two 
reservoirs connected by silicone tubing to each cannula. Perfusion buffer consisted of 1% bovine 
serum albumin in PSS. Once equilibrated at 60 mmHg, the longitudinal pressure gradient was 
increased from zero to 20 mmHg (“control”) or 50 mmHg (“pro-arteriogenic”) 
63
. This was 
achieved by lowering the distal reservoir and raising the proximal reservoir, allowing for the 
average intraluminal pressure to be maintained at 60 mmHg. The control flow rate was ~75 
µL/min, and the “pro-arteriogenic” flow rate was ~170 µL/min. Vessels were then perfused for 
2h. Function of the vessel wall was determined at the end of perfusion by assessing the 
vasoconstrictive response to epinephrine and vasodilator response to acetylcholine, based on 
changes in vessel diameter measured by video micrometer. 
Cell culture. Human coronary artery endothelial cells (HCAEC) and human coronary 
artery smooth muscle cells (HCASMC) were purchased from Lonza. For HCASMC, donors 
included a 12 year old male, a 56 year old female, and a 30 year old male, while HCAEC donors 
were a 21 year old male and a 30 year old male. HCAEC were cultured in EBM-2 basal media 
supplemented with EGM-2 MV SingleQuot factors (HCAEC complete media, Lonza). HCASMC 
were cultured in SMBM basal media supplemented with SmGM-2 SingleQuot factors (HCASMC 
complete media, Lonza). All cells were grown in a humidified incubator in 5% CO2 at 37°C. 
Cells were used between passage five and six for all experiments. Serum reduced media for 
experiments to be performed in room air was prepared by diluting the appropriate complete media 
in low glucose DMEM (Hyclone, Fisher) at a ratio of 2:3 yielding a 2% serum media, and 
supplementing with 15 mmol/L HEPES. Phenol red free media was used for experiments 
requiring fluorescent assays. 
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Co-culture model. To model the vessel wall in vitro, porous Transwell inserts (Corning 
Costar, 0.4 μm pore size) were used as described in the literature
240
. Inserts were inverted and the 
bottom surface was coated with 0.1% gelatin in DMEM, then were placed in a humidified 




) were then seeded onto the 
inverted insert, and inserts were returned to the incubator overnight. The following day, the 
inserts were placed into 6 well plates containing SmGM-2 media and incubated for an additional 
24 h. The top surface of the insert was then coated with 0.1% gelatin in DMEM and incubated for 
1 h. HCAEC (25,000/cm
2
) were then seeded on the top surface of the insert. EGM-2 MV was 
added to the insert and the system was again incubated overnight. When possible, HCASMC and 
HCAEC donors were matched. Confluence of the co-cultures was confirmed by Hoffman 
modulation contrast microscopy (Olympus IX71). Lastly, the confluent co-cultures were 
incubated in serum reduced media for 24 h prior to experiments. For HCAEC mono-culture 
experiments, no HCASMC were seeded on the bottom of the insert, but cultures were otherwise 
processed as described above.   
Shear stress exposure. Only the HCAEC layer of the co-culture was directly exposed to 
FSS. FSS was applied using a cone and plate viscometer shearing system. The system consisted 
of four ultra-high molecular weight polyethylene 0.5° cones connected to microstepper motors 
(Optimal Engineering Systems, Inc.) linked to a controller unit (Optimal Engineering Systems, 
Inc.) (Fig. 1 A). Cones were placed into the four peripheral inserts of the 6-well plate, while the 
central two inserts were not exposed to FSS and were used as a static control. Co-cultures were 
then exposed to one of two pulsatile FSS waveforms, based on previously published information 
241
. The “normal” waveform had time-averaged FSS of 0.07 Pa (Fig. 1B), and modeled flow 
through a quiescent collateral vessel downstream of a patent coronary artery. The “high” 
waveform had time-averaged FSS of 1.24 Pa (Fig. 1C), and modeled flow through an actively 
remodeling collateral vessel downstream of a coronary artery with 60% stenosis. Shear 
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experiments were performed on a laboratory benchtop in HEPES-buffered media with 
temperature maintained at 37°C. Cocultures were exposed to FSS for 2 h. Culture media and/or 
cell lysates were collected for analysis at various time points from pre-shear to 0-24 h post-shear. 
 
siRNA knockdown experiments. HCAEC were seeded into 6-well plates at a density of 
210,000 cells/well. After 24 h, cells were transfected with either PLGF siRNA (sense, 5’-
AGGUGGAAGUGGUACCCUU-3’, overhang dTdT; antisense, 5’-
AAGGGUACCACUUCCACCU-3’, overhang, dCdT), predesigned Nox4 siRNA (Silencer 
Select; s27013) or negative control siRNA (Silencer no.1 siRNA; scRNA), all purchased from 
Invitrogen. Prior to addition to cells, 5 nM of siRNA was precomplexed with lipofectamine 
RNAiMAX transfection reagent (Invitrogen) in Opti-MEM media (Gibco) for 20 minutes. Cells 
were exposed to transfection media (DMEM + 10% FBS containing precomplexed siRNA) for 6 
h, after which cells were trypsinized and seeded onto the upper surface of inserts precoated with 
0.1% gelatin. The lower surface of the inserts had been previously seeded with wild type 
HCASMC, as described above. Co-cultures were incubated overnight in reduced serum media as 
described above before exposure to shear stress. In a separate group of co-cultures, HCASMC 
were transfected similarly to HCAEC, after seeding onto the lower surface of inserts. At the end 
of the transfection period, untreated HCAEC were then seeded onto the upper surface as above. 
Cell specificity and efficacy of target mRNA knockdown was determined by real time PCR. 
PLGF ELISA. Media samples were collected from sheared cells and their corresponding 
static controls, treated with protease inhibitor cocktail (1 mM PMSF, 1 mM Na3VO4, 1 µg/ml 
leupeptin, 1 mM benzamidine-HCl, 1µg/ml aprotinin, 1µg/ml pepstatin A) and stored at -80°C 
until further processing. PLGF was measured using the DuoSet ELISA development kit (R&D 
Systems) according to manufacturer’s protocol. All samples were assayed in duplicate. Data were 
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normalized to total protein concentration, as determined by BCA assay (Pierce). All assay plates 
were read on a Biotek Synergy HT plate reader. 
Real time PCR. After exposure to shear stress and media collection, cells were rinsed 
gently with PBS (HyClone) and trypsinized (TrypLE Express, Gibco). Collected cells were then 
resuspended in 1% β-mercaptoethanol in RLT lysis buffer (Qiagen) and frozen at -80°C for later 
processing. Cannulated vessels were placed in RLT lysis buffer immediately after perfusion and 
sonicated on ice using a Model D 100 Sonic Dismembrator (Fisher). Total RNA was isolated 
using RNeasy mini columns (Qiagen) following manufacturer’s directions. Total RNA quantity 
and quality were determined spectrophotometrically using a Take3 Micro-Volume Plate in a 
Synergy HT plate reader (Biotek). Reverse transcription was carried out using the QuantiTect 
reverse transcription kit (Qiagen) following manufacturer’s instructions. Real time PCR was 
performed on an ABI 7500 Fast instrument (Applied Biosystems) using PerfeCTa SYBR Green 
FastMix, Low ROX (Quanta Biosystems). Relative abundance of target mRNA was determined 
using the comparative Ct method and the following primer pairs: human PLGF forward 5’-
CCTACGTGGAGCTGACGTTCT-3’;  reverse 5’-TCCTTTCCGGCTTCA TCTTCT-3’, human 
Nox1 forward 5’-TTGGAGCAGGAATTGGGGTC-3’;  reverse 5’- 
AATGCTGCATGACCAACCTTT -3’, Human Nox2 forward 5’- 
GGGAACTGGGCTGTGAATGA -3’;  reverse 5’-CCAGTGCTGACCCAAGAAGT-3’, Human 
Nox4 forward 5’-GGGGTTAAACACCTCTGCCT-3’;  reverse 5’-
ACACAATCCTAGCCCCAACA-3’, Mouse PLGF forward 5’-
CTGCTGGGAACAACTCAACAGA-3’; reverse 5’GCGACCCCACACTTCGTT-3’. Gene 
expression was normalized to β-actin, as amplified with the following primers: human β-actin 
forward, 5’-TGCCGACAGGATGCAGAAG-3’; human β-actin reverse, 5’-
CTCAGGAGGAGCAATGATCTTGAT-3’; mouse β-actin forward, 5’-
AGTTCGCCATGGATGACGAT-3’; mouse β-actin reverse, 5’-TGCCGGAGCCGTTGTC-3’. 
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The relative stability of β-actin after treatment was determined using the comparative Ct method 
with GAPDH as the housekeeping gene (human GAPDH forward 5’- 
GAAGGTGAAGGTCGGAGTC-3’; human GAPDH reverse 5’- 
GAAGATGGTGATGGGATTTC -3’). No significant change in -actin was detected. 
Hydrogen Peroxide Assay. The effect of shear stress on the H2O2 concentration in co-
culture media was assessed using the Amplex Red Hydrogen Peroxide Assay kit (Invitrogen). 
Samples were collected in dark tubes, kept protected from light, and immediately frozen at -80°C 
until analysis. Further processing of samples was carried out on ice in reduced light conditions 
according to manufacturer’s directions. 
Nitrate/Nitrite Assay. Total nitrate and nitrite concentration was determined in samples of 
culture media from sheared and static control cocultures as an index of total NO production, , 
using the Nitrate/Nitrite Fluorometric Assay kit (Cayman Chemical). 
 Statistical analyses. All data are presented as mean ± SEM. Experiments were replicated 
at least five times. Data were analyzed by either two way repeated measures ANOVA or one way 
ANOVA, as appropriate. Both were followed by Tukey's range test. The level of significance was 
set at p<0.05. 
Results 
Increased fluid shear stress upregulates PLGF expression.  
 To characterize the effects of FSS on PLGF expression, cocultures were exposed to 
either normal or high FSS for 1, 2, or 4 hours. Media was sampled immediately before FSS 
exposure and 0, 4, 8, 12, and 24 h after FSS exposure. Exposure to either FSS waveform for 1 h 
had no significant effect on PLGF protein levels in media (compared to static control) at any time 
point up to 24 h (Fig. 2A). However, 2 h of high FSS significantly increased PLGF protein levels 
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in media starting 8 h after shear exposure, compared to static control conditions. PLGF protein 
levels continued to increase up to 24 h post-shear (Fig. 2B) and returned to static control levels by 
36 h post-shear (data not shown). In contrast to the effect of high FSS, 2 h treatment with normal 
FSS had no significant effect on PLGF protein (Fig. 2B). Exposure to 4 h of FSS coincided with 
increased cell detachment, as subjectively determined by contrast microscopy (data not shown). 
Therefore, 2 h exposure was selected for further experiments.  
To confirm that PLGF is regulated by FSS in intact vessels, we perfused mouse second 
order mesenteric arterioles using either a 50 mmHg longitudinal pressure gradient (high flow) or 
a 20 mmHg longitudinal pressure gradient (normal flow). PLGF mRNA was significantly 
increased after 2 h of perfusion at 50 mmHg, compared to control arterioles perfused at 20 mmHg 
(2.37 ± 0.36 fold of control) (Fig. 2C).  
Smooth muscle cells increase endothelial cells’ responsiveness to fluid shear stress. 
We next sought to determine which cell type in the coculture was responsible for the 
increased PLGF protein expression in response to FSS by analyzing PLGF mRNA in HCAEC 
and HCASMC at 0, 4, 10 and 24 h post-FSS exposure. Neither level of FSS had a significant 
effect on PLGF mRNA in HCASMC (Fig. 3A). High FSS, but not normal FSS, produced an 
immediate and significant increase in PLGF mRNA expression in HCAEC, which was 
maintained until 4 h post-shear (Fig. 3B).  
To further characterize the role of HCAEC in PLGF production by cocultures, PLGF was 
knocked down in either HCAEC or HCASMC using siRNA. PLGF knockdown was confirmed 
by RT-PCR (Fig. 4B, 4D). PLGF knockdown in HCAEC did not affect PLGF mRNA in 
cocultured HCASMC, or vice versa (not shown). Total PLGF expression was drastically and 
significantly decreased in cocultures with siPLGF treated HCAEC and abolished the effect of 
FSS to increase PLGF protein at 24 h post-shear exposure (Fig. 4A). Surprisingly, siPLGF 
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treatment of HCASMC resulted in a significant increase in PLGF protein concentration in 
coculture media, compared to media from cocultures containing untreated or scrambled siRNA 
treated HCASMC (Fig. 4C). siPLGF treatment of HCASMC did not prevent the FSS-induced 
increase in PLGF protein, in contrast to siPLGF treatment of HCAEC.  
To assess the effect of communication between HCAEC and HCASMC on PLGF 
production by EC, we next compared HCAEC monocultures to HCAEC/HCASMC cocultures. 
HCAEC monocultures had significantly lower baseline PLGF protein levels in media, compared 
to HCAEC/HCASMC cocultures (Fig. 5A). In addition, the sensitivity to FSS intensity (normal 
vs. high) appeared to be lost in HCAEC monocultures, since exposure of HCAEC monocultures 
to both normal FSS and high FSS resulted in a significant and similar increase in PLGF protein. 
Furthermore, the effect of FSS in monocultures was transient and was significant only at 8 h post-
shear (Fig. 5B), yielding a time course of PLGF expression that was dissimilar to our 
observations in cocultures. These data suggest that although HCAEC are clearly the primary 
source of PLGF in the coculture model, HCASMC nevertheless play a role in modulating both 
shear-induced and baseline expression of PLGF.   
Expression of PLGF induced by fluid shear stress is dependent on NADPH oxidase.    
We next investigated possible signaling mechanisms mediating upregulation of PLGF by 
FSS. The soluble mediator NO was evaluated first, based on its well-known role in mediating 
FSS-dependent responses in EC. Total nitrite/nitrate concentrations in coculture media were 
determined as a measure of NO production. High FSS, but not normal FSS, significantly 
increased total nitrite/nitrate (1.43 ± 0.14 fold of static control) immediately after exposure (Fig. 
6A). To assess the role of NO in the regulation of PLGF expression, cocultures were treated with 
the NO synthase (NOS) inhibitor L-NG-nitroarginine methyl ester (L-NAME, 100 µM) 30 min 
prior to FSS exposure. Media was then sampled for PLGF protein levels immediately prior to 
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FSS exposure and 24 h post-shear (the time point at which maximal effect of FSS on PLGF 
protein levels in untreated cells was observed; Fig. 2B). Inhibition of NOS by L-NAME had no 
significant effect on the FSS-induced increase in PLGF protein (Fig. 6B). 
We next tested the effect of FSS on H2O2. Both FSS waveforms caused a significant 
increase in H2O2 immediately after exposure (normal, 1.43 ± 0.16, high, 1.35 ± 0.14 fold of static 
control) (Fig. 7A). Treatment with the H2O2 scavenger catalase (500 U/mL) 30 min prior to FSS 
exposure abolished the effect of high FSS on PLGF protein (Fig. 7B), suggesting that H2O2 is a 
key mediator of this response. The effects of catalase were mimicked by the flavoenzyme 
inhibitor diphenyleneiodonium chloride (DPI, 5 µM) (Fig. 7C). Treatment with DPI (5 µM) also 
prevented the increase in PLGF mRNA in arterioles perfused at 50 mmHg compared to 20 mmHg 
(Fig. 7D).  
Nox4 is necessary for the fluid shear stress-induced increase in PLGF and H2O2 in vascular 
cocultures. 
 We next investigated the role of the ROS-producing NAD(P)H oxidases (Nox) as a 
possible source of H2O2 for this pathway. Real time PCR was performed on mRNA isolated from 
static cocultures to determine the relative abundance of mRNA for Nox 1, 2 and 4, three isoforms 
previously implicated in the outward remodeling of coronary vessels (Table 1). In both HCASMC 
and HCAEC, the predominant isoform was Nox4. We next assessed Nox4 mRNA levels in 
cocultures at 0, 4, 10 and 24 h after 2 h of FSS exposure. In HCAEC, Nox4 mRNA was 
significantly increased 4 h after exposure to high FSS (1.42 ± 0.14 fold of static control) and 
returned to control levels by 10 h (Fig 8A). High FSS significantly increased HCASMC Nox4 
mRNA 24 h after exposure (1.60 ± 0.23 fold of control) (Fig 8B). Normal FSS had no significant 
effect on Nox4 mRNA in either cell type. 
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Lastly, in order to determine whether Nox4 plays a role in the FSS induced increase in 
PLGF, we knocked down Nox4 in either HCAEC or HCASMC using siRNA. Knockdown was 
verified by RT-PCR (Fig. 9B, 9D). Nox4 knockdown in HCAEC did not affect Nox4 mRNA in 
cocultured HCASMC, or vice versa (not shown). Knockdown of Nox4 in HCASMC had no 
significant effect on basal levels of PLGF protein and did not affect the response of PLGF to high 
FSS (Fig. 9A). Knockdown of Nox4 in HCAEC abolished the effects of high FSS on PLGF 
protein levels without significantly affecting basal PLGF protein levels (Fig. 9C). Finally, 
knockdown of Nox4 in HCAEC prevented the increase in H2O2 observed immediately after high 
FSS in untreated cells (Fig. 9E).   
 
Discussion 
Our findings demonstrate that PLGF is regulated by FSS both in a vascular cell coculture 
model and in intact vessels, and that this response is sensitive to the magnitude and duration of 
FSS. We identified endothelial cells as the primary cell type producing PLGF in the coculture 
model; however, we also found that endothelial PLGF production is positively influenced by the 
presence of smooth muscle cells. Investigation of the mechanisms involved in FSS-induced 
PLGF expression revealed that this pathway is dependent on H2O2, and identified NADPH 
oxidase 4 (Nox4) as a likely source of H2O2 in this context. Further definition of the molecular 
mechanism by which FSS regulates PLGF may identify new therapeutic targets to either promote 
or inhibit PLGF expression and arteriogenesis, depending on the context (e.g. ischemic 
cardiovascular disease vs. cancer).  
Although the cone and plate viscometer used to generate shear stress in the coculture 
system allows accurate control of the angular velocity of the cone (and thus FSS) in our model, 
exposure times longer than 2 h were prohibited by detachment of the endothelial cells. The 
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possibility that cessation of elevated FSS at the end of the exposure period affects PLGF 
expression (in addition to, or instead of, initiation of elevated FSS) cannot be completely 
excluded. However, the dependence of the PLGF protein response on both the duration and 
magnitude of FSS exposure, and the immediate effect of FSS on PLGF mRNA in both cocultures 
and perfused vessels, suggests that upregulation of PLGF is primarily due to initiation of elevated 
FSS. 
In intact vessels, EC and SMC interact physically and also communicate through secreted 
mediators to maintain normal vessel function. The coculture model used in this study provides a 
close approximation of this situation by allowing for both physical and biochemical interaction. 
Our data show that PLGF is primarily produced by HCAEC in our model, consistent with our 
previously published findings
242
. Indeed, knockdown of PLGF in HCAEC decreased baseline 
media PLGF concentrations to less than 10% of the level in untreated cocultures. Nevertheless, 
HCASMC appear to play a major role in modulating PLGF levels in the coculture system. 
HCAEC/HCASMC cocultures secreted ~2-fold more PLGF than HCAEC monocultures. This 
effect cannot be explained by a simple additive effect of HCASMC PLGF production on total 
PLGF levels, since HCAEC produce ~two orders of magnitude more PLGF than HCASMC
242
. 
Furthermore, knockdown of PLGF in HCASMC cocultures yielded the seemingly contradictory 
result of increased PLGF media levels. One possible explanation for these observations is that 
HCASMC-produced PLGF may exert negative feedback on HCAEC PLGF production, whereas 
other factors generated by HCASMC have a stimulatory effect. Consistent with our findings for 
PLGF, several other growth factors have been reported to increase in endothelial cell/smooth 
muscle cell cocultures compared to endothelial monocultures, including VEGF-A, PDGF-AA, 
PDGF-BB, MCP-1 and TGF-β1
243, 244
. Furthermore, coculture of EC with SMC leads to an 
increase in SMC differentiation
245
, EC elongation, and EC permeability
246
, demonstrating the 
importance of EC/SMC interaction on signaling and function in both cell types. In keeping with 
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these results in static cocultures and monocultures, we found the effect of FSS on PLGF to be 
transient and diminished in HCAEC monocultures, as compared to cocultures. These data suggest 
that HCAEC/HCASMC interaction and signaling is essential for both baseline PLGF expression 
and its upregulation by the physiological stimulus of increased FSS. Dysfunction in either of 
these vascular cell types may therefore lead to abnormal PLGF production and signaling. 
In the vasculature, FSS increases the production of NO by endothelial nitric oxide 
synthase (eNOS). eNOS is localized to the endothelium and is increased six-fold during 
arteriogenesis
247
. Exercise, which has been reported to accelerate arteriogenesis after femoral 
ligation, also increases eNOS expression
5
. Furthermore, treatment with L-NAME inhibits 
collateral growth augmentation by exercise after femoral artery ligation in rats
145
, and mice 
treated with L-NAME either immediately after femoral artery ligation or 3 d post-operatively 
show significant decreases in flow recovery compared to control
147
. eNOS knockout mice also 
exhibit diminished flow recovery after femoral artery excision
141
, and the arteriogenic effect of 
bFGF in rats is dependent on NOS activity
143
.  We verified that the high FSS condition used in 
this study was sufficient to increase NO production, as expected. Despite NO being an important 
arteriogenic factor
141, 145, 248
, inhibition of NO production with L-NAME had no effect on the FSS-
induced expression of PLGF in our model system. As noted above, eNOS knockout mice exhibit 
diminished arteriogenesis after femoral artery occlusion
141
.  However, collateral growth in these 
mice has been demonstrated to “catch up” with that in wild type mice later in the arteriogenic 
process
146
. It should be noted that our model exposes the endothelium to FSS without changes in 
other parameters relevant to arteriogenesis (stretch, hypoxia). Stretch has been shown to induce 
PLGF expression in human bronchial airway epithelial cells in a NO dependent fashion
249
. Thus, 
although NO does not appear to be required for the upregulation of PLGF by FSS, the potential 
role of stretch-induced NO production in modulating PLGF expression in vascular cells during 
arteriogenesis remains to be investigated. Likewise, our group previously demonstrated 
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upregulation of PLGF protein in HCAEC by hypoxia 
250
, and potential interactions between FSS 
and hypoxia in regulation of PLGF also remain to be characterized. 
The role of ROS in arteriogenesis has been clearly demonstrated in numerous studies 
evaluating the effects of antioxidants on collateral growth. Oxidative stress exerts a strong 
inhibitory effect on collateral remodeling. For instance, induction of oxidative stress by knockout 
of endothelial specific superoxide dismutase (SOD, which dismutates O2
•−
, the superoxide radical 
anion, to H2O2) impairs flow recovery in mouse ischemic hindlimb
198
. Interestingly, suppression 
of ROS generation is also inhibitory. In the dog, the increase in coronary blood flow induced by 
repeated coronary occlusion is inhibited by the antioxidant N-acetylcysteine (NAC)
251
. Similarly, 
in mice the antioxidants NAC, ebselen and Tempol either delay or inhibit blood flow recovery in 
the hind limb following femoral artery ligation
198-200
. These seemingly contradictory observations 
have been made even within studies; in the rat heart, oxidative stress produced by treatment with 
the SOD inhibitor diethyldithiocarbamate (DETC) inhibits the increase in coronary collateral 
blood flow following repeated coronary occlusion in the rat heart, but a similar degree of 
inhibition is also observed when ROS generation was suppressed with either DPI or the Nox 
inhibitor apocynin 
201
. These contradictory results suggest that arteriogenesis requires an optimal 
ROS concentration. An alternative interpretation is that H2O2 may be an important regulator of 
arteriogenesis. Nox inhibition results in a decreased production of both H2O2 and O2
•−
, whereas 
inhibiting SOD would also result in decreased H2O2, but increased O2
•−
. Taken together, these 
data suggest a potential positive role for H2O2 in regulating arteriogenesis.  
In the vasculature, the predominant sources of ROS are Nox, xanthine oxidases, 
uncoupled eNOS, and the mitochondrial electron transport chain. Of these, Nox are the only 
family of enzymes that produce ROS as their primary function, rather than as a byproduct 
252
. 
Nox-derived ROS activates several pro-arteriogenic signaling pathways, including Akt, MAPK, 
Src and PKC
253, 254
. Consistent with these findings, various Nox isoforms are also implicated in 
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collateral remodeling in vivo 
200, 255-257
. Furthermore, FSS increases both Nox expression and Nox-
derived ROS generation 
258-260
, and Nox isoforms colocalize with the mechanosensing machinery 
of the cell
261, 262
. We report that the Nox inhibitor DPI abrogates the effects of FSS on PLGF 
expression in both vascular cell cocultures and intact perfused vessels. In our in vitro model, we 
found Nox4 to be the predominant Nox isoform,  consistent with previous reports for both 
endothelial
263
 smooth muscle cells
264
. Nox 4, unlike other Nox isoforms, is constitutively active 
and only requires association with p22phox for its activity; furthermore, it uniquely produces 
mostly H2O2, rather than O2 
265
. Interestingly, Nox4 activity does not result in peroxynitrite 
production and NO inactivation
266
, both of which are linked to vascular Nox activation 
267, 268
. 
Indeed, endothelial-specific Nox4 overexpression in mice results in increased H2O2 production 
and vasodilation, along with lower systemic blood pressure
269
. These mice also exhibit 
accelerated flow recovery following induction of hindlimb ischemia 
257
. Furthermore, similarly to 
PLGF knockout mice, mice lacking Nox4 fail to recover hindlimb perfusion after femoral artery 
ligation 
256
. In this study, we found both endothelial and smooth muscle Nox4 mRNA to be 
increased by high FSS in our coculture system. siRNA knockdown of Nox4 in HCAEC 
attenuated the effects of shear stress on both PLGF and peroxide, whereas Nox4 knockdown in 
HCASMC did not alter the effects on FSS on PLGF expression, suggesting that endothelial Nox4 
plays an important role in the regulation of PLGF by FSS and ROS. 
In this study, we report that pro-arteriogenic FSS increases PLGF protein levels by ~40% 
compared to static control. Although the magnitude of the effect is not large, studies in humans 
suggest that a PLGF increase in this range is likely to be physiologically significant. Patients 
categorized as having “rich” coronary collaterals (Rentrop classification 2 and 3) were found to 
have 40% higher plasma PLGF levels compared to patients with “poor” coronary collaterals 
(Rentrop classification 0 and 1)
270
. These clinical observations suggest that the increase observed 
in our human in vitro model could have a significant effect on human coronary collateral 
circulation in vivo.  
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Our findings that FSS-stimulated ROS production is a key signal for PLGF expression 
raise questions about the growing use of antioxidants as a prophylactic measure in healthy 
individuals. While antioxidants may be beneficial in individuals with oxidative stress (by 
returning ROS to physiological levels), our data and that of others supporting the “redox 
window” hypothesis suggest that overuse of antioxidants could potentially inhibit beneficial 
collateral remodeling. It is therefore of interest to determine the effects of impaired oxidative 
balance on shear-induced PLGF expression. 
In summary, we provide the first demonstration that the important arteriogenic growth 
factor PLGF is upregulated in cocultured vascular cells and isolated vessels by the key 
arteriogenic stimulus of FSS. We further show that this response is mediated by a novel signaling 
pathway involving H2O2 and Nox4, and that it is influenced by EC/SMC interaction. These 
findings have important clinical implications, as a better understanding of the molecular 
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Figure 1. (A) Illustration of coculture system with cone in place. Transwell inserts were placed 
inside 6 well plates. HCAEC were seeded on the top side of the insert, while HCASMC were 
seeded on the underside. The pore size (0.4 µm) prevented either cell type from migrating 
79 
 
completely through the membrane, but was readily permeable to soluble factors and allowed 
some direct cell-cell contact. (B) and (C) Shear stress wave forms used in this study, shown over 
1 cardiac cycle (0.9 sec). (B) Waveform representing shear stress in a collateral arising from a 
coronary artery free of stenosis. (C) Waveform representing shear stress in a collateral arising 




Figure 2. Effect of fluid shear stress exposure on PLGF expression in the vessel wall. (A) 
Cocultures were exposed to static control conditions (no FSS), normal shear stress (0.07 Pa) or 
81 
 
high FSS (1.24 Pa). PLGF protein in medium was assessed prior to shear exposure and up to 24 h 
post-shear. (A) Neither waveform had a significant effect on PLGF protein levels after 1h of 
exposure (n=5). (B) 2h exposure to high FSS, but not normal FSS, induced a significant increase 
in PLGF protein compared to static control starting 8h after shear exposure which remained 
evident up to 24 h (*n=5, p<0.001). (C) Mesentery arterioles (~150 µm ID) were cannulated and 
perfused with 1% BSA-PSS for 2h. Perfusion with a pressure gradient of 50mmHg significantly 




Figure 3. Fluid shear stress primarily affects PLGF expression in HCAEC. (A) HCASMC showed 
no significant change in PLGF gene expression, regardless of the level of shear exposure received 
by the coculture (n=5). HCASMC were not directly exposed to FSS. (B) HCAEC demonstrated 
an immediate increase in PLGF gene expression in response to high FSS which was maintained 
for up to 4 h after shear exposure (*n=5, p<0.001). Normal FSS had no significant effect on 




Figure 4. PLGF is predominantly produced by HCAEC. PLGF expression was knocked down 
using siRNA in HCAEC (A-B) or HCASMC (C-D). Media was sampled immediately prior to 
exposure to 2 h of high FSS and 24 h after. In cocultures containing siPLGF-treated HCAEC (A), 
PLGF was significantly decreased compared to levels in untreated cocultures prior to shear 
(*n=5, p<0.001), and failed to increase in response to FSS (*n=5, p<0.001). Cocultures with 
siSCR treated HCAEC showed a slight but significant decrease in pre-shear PLGF levels 
compared to untreated cells (*n=5, p<0.001); however, exposure to high FSS significantly 
increased PLGF as expected (n=5, † p<0.05). (B) Knockdown of PLGF in HCAEC was 
confirmed by real time PCR (*n=5, p<0.01). (C) PLGF knockdown in HCASMC resulted in a 
significant increase in total PLGF protein in the media compared to untreated cocultures prior to 
shearing (*n=5, p<0.001). PLGF was further increased by exposure to high FSS in both siSCR 
and siPLGF treated groups, as compared to static untreated controls (*n=5, p<0.001) and the 
corresponding pre-shear values for each treatment condition (†n=5, p<0.05).  (D) Real time PCR 
confirmed PLGF knockdown in HCASMC (*n=5, p<0.01). 
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Figure 5. Effect of FSS exposure on PLGF production in HCAEC monoculture. (A) The baseline 
(unstimulated) level of PLGF protein was significantly lower in medium of HCAEC 
monocultures than in medium from HCAEC/HCASMC cocultures (*n=5, p<0.001). (B) HCAEC 
monocultures were exposed to static conditions, normal FSS, or high FSS for 2h as done for 
cocultures. Culture media was sampled pre- and post-shear. Both high FSS and normal FSS 
induced a significant increase in PLGF protein, but only at 8 h post-shear (*n=5, p<0.05). Thus, 





Figure 6. Fluid shear stress increases nitric oxide production but is not required for the FSS-
induced increase in PLGF protein. (A) High FSS, but not normal FSS, significantly increased 
nitrite/nitrate levels immediately after shear exposure, compared to static control (*n=5, p<0.01). 
(B) The nitric oxide synthase inhibitor L-NAME (100 μmol/L) had no effect on the shear induced 





Figure 7. Hydrogen peroxide is required for FSS to upregulate PLGF expression. (A) Both high 
and normal FSS significantly increased H2O2 immediately after shear exposure, compared to 
static control in cocultures (*n=5, p<0.05). (B) Catalase (500 U/mL) blocked the effect of FSS to 
upregulate PLGF (*n=5; p<0.01). (C) DPI (5 μmol/L) also prevented the increase in PLGF 
protein in response to FSS, and further decreased PLGF protein below static control levels (*n=5; 
p<0.01). (D) DPI (5 μmol/L) also inhibited the flow induced increase in PLGF mRNA in 
cannulated arterioles. (20 mmHg n=6, 50 mmHg n=5, DPI + 50 mmHg n=4, p<0.01). 
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Table 1. Relative Nox isoform/β-actin mRNA. 
 
Nox1 Nox2 Nox4 
HCAEC 1.00 ± 0.09 0.30 ± 0.05 1164.14 ± 60.43*† 
HCASMC 1.17 ± 0.11 0.97 ± 0.14 15.92 ± 2.57*† 
 
Values are shown as means ± SEM. Real time PCR revealed Nox4  to be the predominant 




Figure 8. Nox4 is upregulated by shear stress. (A) In HCAEC, high FSS significantly increased 
Nox4 mRNA compared to static control while normal FSS had no significant effect on Nox4 






Figure 9. Endothelial Nox4 is the source of FSS induced hydrogen peroxide. (A) Knockdown of 
Nox4 in HCASMC in cocultures had no significant effect on the FSS-induced increase in PLGF 
protein (n=5, vs. static * p<0.01, vs. pre-shear † p<0.05). (B) Knockdown of Nox4 in HCASMC 
was confirmed by real time PCR (n=5, * p<0.01). (C) High FSS increased PLGF protein levels in 
HCAEC compared to pre-shear levels (n=5, † p<0.05). Knockdown of Nox4 in HCAEC in 
cocultures inhibited the FSS-induced increase in PLGF protein and significantly decreased PLGF 
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below static control. (n=5, * p<0.01). (D) Real time PCR confirmed knockdown of Nox4 in 
HCAEC (n=5, * p<0.01) (E) knockdown of NOX in HCAEC also attenuated the effects of high 
FSS on hydrogen peroxide, identifying endothelial Nox4 as a key source of FSS induced 

























Increased fluid shear stress (FSS) is a key initiating stimulus for arteriogenesis, the outward 
remodeling of collateral arterioles in response to upstream stenosis or occlusion, and placental 
growth factor (PLGF) is an important arteriogenic mediator. We previously showed that elevated 
FSS increases PLGF in a reactive oxygen species (ROS)-dependent fashion both in vitro and ex 
vivo. Heme oxygenase 1 (HO-1) is a cytoprotective enzyme that is upregulated by stress and has 
arteriogenic effects.  In the current study, we used a coculture model of human coronary artery 
endothelial cells (EC) and smooth muscle cells (SMC) to test the hypothesis that HO-1 mediates 
the effects of FSS on PLGF. Cocultures were exposed to arteriogenic FSS as we previously 
described. We also exposed mesenteric arterioles ex vivo to either high or low flow. HO-1 mRNA 
was increased by conditions of increased flow and shear stress in both cocultures (~1.5 fold) and 
vessels (~15 fold). Both inhibition of HO-1 with zinc protoporphyrin (30 µM) and HO-1 
knockdown abolished the effect of increased flow on PLGF. Conversely, induction of HO-1 with 
hemin (2.5-40 µM) increased PLGF ~1.6 fold. Cocultures were then treated with a CO donor 
(CORM-A1), biliverdin, or ferric ammonium citrate (FAC). Only FAC (10-200 µg/ml) increased 
PLGF (~2-fold). Paradoxically, the iron chelators 1,10-phenanthroline (100 µM) and 
deferoxamine (100 µM) also significantly increased secreted PLGF compared to DMSO vehicle 
control (~1.3 fold; n=5, p<0.01). Finally, we demonstrated that hypoxia increases PLGF 
expression in an endothelial HO-1 dependent fashion. We conclude that the regulation of PLGF 
by FSS is mediated by a HO-1 dependent mechanism, and that HO-1 is a common mediator of 
both hypoxia and FSS effects on PLGF by decreasing intracellular labile iron and suggest a role 
for iron sensitive transcription factors.  
Keywords: arteriogenesis, collateral circulation, hemodynamics, endothelium, vascular 




Coronary artery disease (CAD) is a major cause of death worldwide
271, 272
. The primary predictor 
of survival for CAD patients is the number of preexisting collateral vessels (arterial – arterial 
anastomoses) and the degree to which they have remodeled outward to increase their flow 
capacity
130, 273
. This outward remodeling occurs in response to increased flow through the vessels, 
which is generated by an increase in the pressure gradient across the vessels due to decreased 
downstream pressure in the occluded branch. This remodeling process is termed arteriogenesis. 
Pharmacological stimulation of arteriogenesis has been a long sought after goal, because of the 
potential of arteriogenesis to reduce mortality and morbidity in CAD. However, early attempts to 
induce arteriogenesis via administration of single exogenous growth factors were marred with 
failure
274
, and it has become clear that a deeper understanding of the myriad of signaling events 
contributing to arteriogenesis is necessary to develop safe and effective pro-arteriogenic 
treatments. 
 Placental growth factor (PLGF) is a member of the vascular endothelial growth factor 
(VEGF) family. PLGF is a potent arteriogenic agent, even more so than VEGF-A
10, 11
. PLGF 
exclusively binds fms-like tyrosine kinase-1 (VEGFR-1) and elicits distinct downstream signaling 
events than those induced by VEGF-A binding of VEGFR-1
161
. PLGF exacts its arteriogenic 
effect by recruitment of monocytes (which only express VEGFR-1) to the vascular wall
10, 168, 275
. 
PLGF knockout mice exhibit a blunted arteriogenic response to hindlimb ischemia 
10
, whereas 
PLGF protein levels in coronary artery plasma are positively correlated with improved patient 
outcome following myocardial infarction
238
. 
 Heme oxygenase (HO) catabolizes heme into equimolar quantities of CO, divalent iron, 
and biliverdin. There are two isoforms of HO; an inducible isoform (HO-1) and a non-inducible, 
constitutively expressed isoform (HO-2). HO-2 is constitutively expressed in the testes
276





. HO-1, on the other hand, is strongly induced in response to cellular stresses such as 
increased reactive oxygen species (ROS) and radiation. There are only two reported cases of HO-
1 deficiency in humans. These patients exhibited severe growth retardation and endothelial 
dysfunction, along with abnormal hemostasis and an increased susceptibility to oxidative stress
278-
280
. HO-1 knockout mice present with similar growth abnormalities and appear to be in a chronic 
inflammatory state
281
. Arteriogenesis is diminished with advanced age
282
 and this effect may be 
related to abnormal HO-1 expression and/or signaling, since induction of HO-1 in aged rats with 




 We previously reported that exposure to arteriogenic FSS increases PLGF protein and 
mRNA both in vitro in a coculture model of the vessel wall and ex vivo in isolated mouse 
mesenteric arterioles. We also reported that this increase is dependent on FSS-induced production 
of hydrogen peroxide by endothelial NADPH oxidase 4 (Nox4). It is established that FSS also 
increases activation and expression of HO-1 in endothelial cells 
258, 284, 285
, and that these effects 
are dependent on ROS produced by Nox isoforms 
258, 284
. Similarly, HO-1 is upregulated in 
hindlimb skeletal muscle following femoral artery ligation 
256, 286
 in a Nox-dependent manner
256
.  
A possible link between HO-1 and PLGF is suggested by the observation that PLGF and HO-1 
expression are both significantly increased in hindlimb skeletal muscle early after femoral artery 
ligation
118
. Furthermore, HO-1 haploinsufficiency in mice causes a decrease in PLGF expression 
and reduces the extent of revascularization following induction of hindlimb ischemia 
287
. Lastly, 
HO-1 knockout increases the expression of anti-arteriogenic soluble VEGFR-1
288
. Therefore, we 
hypothesized that the effects of FSS on PLGF are mediated by HO-1. We tested this hypothesis in 
an endothelial cell/smooth muscle cell coculture model and in isolated mouse mesenteric 





Reagents. All reagents were purchased from Sigma-Aldrich unless otherwise specified. 
 
Perfused arterioles. All animal experimental procedures were approved by the 
Institutional Animal Care and Use Committee at Oklahoma State University. Experiments were 
conducted on isolated second order mesenteric arterioles (≈120-180 μm) of 6-8 week old 
C57BL/6J male mice (Jackson Laboratories). Mice were deeply anesthetized with isoflurane 
delivered by a vaporizer and the heart was excised. The entire mesentery, with the superior 
mesenteric artery and vein, was dissected free and washed with 4ºC PBS. Second order 
mesenteric arterioles were isolated from the mesenteric tissue. The isolated arterioles were 
transferred to a vessel chamber at 4ºC (Living Systems Instrumentation). The chamber contained 
a pair of glass micropipettes and was filled with physiological saline solution (PSS) (142 mM 
NaCl, 4.7 mM KCl, 1.7 mM MgSO4, 0.5 mM EDTA, 2.79 mM CaCl2, 10 mM HEPES, 1.18 mM 
KH2PO4, pH 7.4). After cannulation of the proximal (upstream) end of the vessel, the intraluminal 
pressure was gradually raised (less than 20 mmHg) to clear the lumen of clotted blood. Once 
cleared, the distal (downstream) end of the vessel was also cannulated. Time from euthanasia to 
complete cannulation was under 60 minutes. The temperature of the bath was then raised to 37ºC 
and pressure was gradually raised to 60 mmHg (~10 mmHg/10 minutes). The pressure increase 
was achieved by gradually raising two reservoirs connected by silicone tubing to each cannula. 
Perfusion buffer consisted of 1% bovine serum albumin in PSS. Once equilibrated at 60 mmHg, 
the longitudinal pressure gradient was increased from zero to 20 mmHg (“control”) or 50 mmHg 
(“pro-arteriogenic”) 
63
. This was achieved by lowering the distal reservoir and raising the 
proximal reservoir, allowing for the average intraluminal pressure to be maintained at 60 mmHg. 
The control flow rate was ~75 µL/min, and the “pro-arteriogenic” flow rate was ~170 µL/min. 
Vessels were then perfused for 2h. Function of the vessel wall was determined at the end of 
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perfusion by assessing the vasoconstrictive response to epinephrine and the vasodilator response 
to acetylcholine, as assessed by changes in vessel diameter measured by video micrometer. 
Cell culture. Human coronary artery endothelial cells (HCAEC) and human coronary 
artery smooth muscle cells (HCASMC) were purchased from Lonza. For HCASMC, donors 
included a 12 year old male, a 56 year old female, and a 30 year old male, while HCAEC donors 
were a 21 year old male and a 30 year old male. HCAEC were cultured in EBM-2 basal media 
supplemented with EGM-2MV SingleQuot factors (HCAEC complete media, Lonza). HCASMC 
were cultured in SMBM basal media supplemented with SmGM-2 SingleQuot factors (HCASMC 
complete media, Lonza). All cells were grown in a humidified incubator in 5% CO2 at 37°C. 
Cells were used at passage five or six for all experiments. Serum reduced media for experiments 
to be performed in room air was prepared by diluting the appropriate complete media in low 
glucose DMEM (Hyclone, Fisher) at a ratio of 2:3 yielding a 2% serum media, and 
supplementing with 15 mmol/L HEPES. 
Co-culture model. To model the vessel wall in vitro, porous Transwell inserts (Corning 
Costar, 0.4 μm pore size) as we previously described 
289
. Inserts were inverted and the bottom 
surface was coated with 0.1% gelatin in DMEM, then were placed in a humidified incubator in 




) were then seeded onto the inverted insert, and 
inserts were returned to the incubator overnight. The following day, the inserts were placed into 6 
well plates containing SmGM-2 media and incubated for an additional 24 h. The top surface of 
the insert was then coated with 0.1% gelatin in DMEM and incubated for 1 h. HCAEC 
(25,000/cm
2
) were then seeded on the top surface of the insert. EGM-2MV was added to the 
insert and the system was again incubated overnight. When possible, HCASMC and HCAEC 
donors were matched. Confluence of the co-cultures was confirmed by Hoffman modulation 
contrast microscopy (Olympus IX71). Lastly, the confluent co-cultures were incubated in serum 
reduced media for 24 h prior to experiments. For HCAEC mono-culture experiments, no 
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HCASMC were seeded on the bottom of the insert, but cultures were otherwise processed as 
described above.   
Shear stress exposure. Only the HCAEC layer of the co-culture was directly exposed to 
FSS. FSS was applied using a cone and plate viscometer shearing system as we previously 
described
289
. Co-cultures were then exposed to a pulsatile FSS waveform that had a time-
averaged FSS of 1.24 Pa. This waveform is based on previously published information 
241
. Shear 
experiments were performed on a laboratory benchtop in HEPES-buffered media with 
temperature maintained at 37°C. Cocultures were exposed to FSS for 2 h. Culture media and/or 
cell lysates were collected for analysis at various time points, from pre-shear up to 24 h post-
shear. 
Hypoxia exposure. Cells were treated as above and placed in a pre-warmed humidified 
cell culture chamber (Stem Cell Technologies). The chamber was then flushed with a mixture of 
94% nitrogen, 5% carbon dioxide, and 1% oxygen. The chamber was then placed in a 37°C 
incubator for the indicated time. 
siRNA knockdown experiments. HCAEC were seeded into 6-well plates at a density of 
210,000 cells/well. After 24 h, cells were transfected with either predesigned HO-1 siRNA 
(Silencer Select; s194530) or negative control siRNA (Silencer no.1 siRNA; scRNA), all 
purchased from Invitrogen. Prior to addition to cells, 5 nM of siRNA was precomplexed with 
lipofectamine RNAiMAX transfection reagent (Invitrogen) in Opti-MEM media (Gibco) for 20 
min. Cells were exposed to transfection media (DMEM + 10% FBS containing precomplexed 
siRNA) for 6 h, after which cells were trypsinized and seeded onto the upper surface of inserts 
precoated with 0.1% gelatin. The lower surface of the inserts had been previously seeded with 
wild type HCASMC, as described above. Co-cultures were incubated overnight in reduced serum 
media as described above before exposure to shear stress. In a separate group of co-cultures, 
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HCASMC were transfected similarly to HCAEC, after seeding onto the lower surface of inserts. 
At the end of the transfection period, untreated HCAEC were then seeded onto the upper surface 
as above. Cell specificity and efficacy of target mRNA knockdown was determined by real time 
PCR. 
PLGF ELISA. Media samples were collected from treated cells and their corresponding 
controls, treated with protease inhibitor cocktail (1 mM PMSF, 1 mM Na3VO4, 1 µg/ml leupeptin, 
1 mM benzamidine-HCl, 1 µg/ml aprotinin, 1 µg/ml pepstatin A) and stored at -80°C until further 
processing. Media samples were collected prior to treatment and 24h after treatment (The time at 
which FSS had the greatest effect on PLGF protein
289
) PLGF was measured using the DuoSet 
ELISA development kit (R&D Systems) according to manufacturer’s protocol. All samples were 
assayed in duplicate. Data were normalized to total protein concentration, as determined by BCA 
assay (Pierce). All assay plates were read on a Biotek Synergy HT plate reader. 
Real time PCR. After exposure to shear stress and media collection, cells were rinsed 
gently with PBS (HyClone) and trypsinized (TrypLE Express, Gibco). Collected cells were then 
resuspended in 1% β-mercaptoethanol in RLT lysis buffer (Qiagen) and frozen at -80°C for later 
processing. Cannulated vessels were placed in RLT lysis buffer immediately after perfusion and 
sonicated on ice using a Model D 100 Sonic Dismembrator (Fisher). Total RNA was isolated 
using RNeasy mini columns (Qiagen) following manufacturer’s directions. Total RNA quantity 
and quality were determined spectrophotometrically using a Take3 Micro-Volume Plate in a 
Synergy HT plate reader (Biotek). Reverse transcription was carried out using the QuantiTect 
reverse transcription kit (Qiagen) following manufacturer’s instructions. Real time PCR was 
performed on an ABI 7500 Fast instrument (Applied Biosystems) using PerfeCTa SYBR Green 
FastMix, Low ROX (Quanta Biosystems). Relative abundance of target mRNA was determined 
using the comparative Ct method and the following primer pairs: human PLGF forward 5’-
CCTACGTGGAGCTGACGTTCT-3’;  reverse 5’-TCCTTTCCGGCTTCA TCTTCT-3’, : human 
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HO-1 forward 5’-CTGCGTTCCTGCTCAACATC-3’;  reverse 5’-
GGCAGAATCTTGCACTTTGTTG-3’, Mouse PLGF forward 5’-
CTGCTGGGAACAACTCAACAGA-3’; reverse 5’-GCGACCCCACACTTCGTT-3’, Mouse 
HO-1 forward 5’- TCGTGCTCGAATGAACACTCTG-3’; reverse 5’ -
AGCTCCTCAAACAGCTCAATGT -3’. Gene expression was normalized to β-actin, as 
amplified with the following primers: human β-actin forward, 5’-
TGCCGACAGGATGCAGAAG-3’; reverse, 5’-CTCAGGAGGAGCAATGATCTTGAT-3’; 
mouse β-actin forward, 5’-AGTTCGCCATGGATGACGAT-3’; reverse, 5’-
TGCCGGAGCCGTTGTC-3’. Relative gene expression was quantified using the ΔΔCt method.  
Statistical analyses. All data are presented as mean ± SEM. Experiments were replicated 
at least five times. Data were analyzed by either two-way repeated measures ANOVA or one-way 
ANOVA, as appropriate. Both were followed by Tukey's range test. The level of significance was 
set at p<0.05. 
Results 
 To determine if HO-1 plays a role in the vascular response to shear stress, we first 
determined the relative mRNA levels of HO-1 in our models following experimental treatment. In 
endothelial cells (Fig. 1A), shear stress significantly increased HO-1 mRNA immediately after 
exposure (1.40 ± 0.08 fold of static control), and this increase remained evident 4 h after exposure 
(1.54 ± 0.18 fold of static). By 10 h after exposure, HO-1 mRNA was not significantly different 
from control. In smooth muscle cells (Fig. 1B), HO-1 mRNA was significantly increased 4h after 
exposure to shear stress (1.29 ±0.11 fold of static), and remained elevated 10 h post exposure 
(1.41 ± 0.13 fold of static). Mouse mesenteric arterioles (Fig. 1C) exposed to elevated flow 
(generated by a 50 mmHg pressure gradient) expressed significantly higher levels of HO-1 
mRNA compared to vessels subjected to normal flow (generated by a 20mmHg pressure 
gradient) (14.43 ± 4.48 fold of 20 mmHg).  
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We previously reported that FSS increases PLGF expression both in our coculture model 
and in perfused vessels
289
. To determine whether HO-1 is a component of the signaling pathway 
mediating this response, we first tested the effect of zinc protoporphyrin IX (ZnPP), a HO-1 
inhibitor, on the FSS-induced increase in PLGF expression. ZnPP (30 µM) blocked the effect of 
FSS on PLGF, and even decreased PLGF protein below static control levels (Fig. 2A). Similarly, 
in perfused vessels ZnPP (30 µM) prevented the effect of increased flow on PLGF mRNA (Fig. 
2B). To determine the relative importance of endothelial cell vs smooth muscle cell HO-1 activity 
in mediating the effects of FSS on PLGF expression, HO-1 was separately knocked down in each 
cell type in the coculture model using siRNA (Fig. 3). HO-1 knockdown in endothelial cells 
prevented the FSS-induced expression of PLGF (Fig. 3A). In contrast, knockdown of HO-1 in 
smooth muscle cells did not affect the FSS-mediated increase in PLGF (Fig 3B). Knockdown in 
either cell type was confirmed by real time PCR (Fig 3C, 3D). HO-1 knockdown in endothelial 
cells did not affect HO-1 mRNA in cocultured smooth muscle cells, or vice versa (Fig. 3E, 3F). 
In agreement with these results, stimulating HO-1 with hemin chloride (2.5-40 µM) significantly 
increased PLGF protein levels in coculture media after 24 h (Fig. 4A).  
 HO-1 activity generates three products (biliverdin, carbon monoxide, and free iron). We 
next tested whether one or more of these molecules could upregulate PLGF expression in 
vascular cell cocultures. Treatment with 100 µM biliverdin (which is also a negative feedback 
inhibitor of HO-1) significantly decreased PLGF protein (0.70 ± 0.06 fold of control) after 24 h 
(Fig. 4B). To determine whether CO modulates PLGF expression, we treated cocultures with a 
CO-releasing molecule (CORM-A1, 0-400 µM) for 24h (Fig. 4C). Similarly to biliverdin, 
CORM-A1 significantly decreased secreted PLGF at the 200 µM (0.90 ± 0.03 fold of control) and 
400 µM (0.86 ± 0.02 fold of control) doses. Lastly, we tested the effect of iron on PLGF 
expression. Divalent iron in the form of ferrous ammonium sulfate (FAS, 10-200 µM) had no 
significant effect on PLGF expression after 24 h (Fig 4D). In contrast, trivalent iron in the form of 
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ferric ammonium citrate (FAC, 10-200 µg/ml) mimicked the effects of hemin chloride and 
significantly increased PLGF levels after 24 h (Fig. 4E). 
Surprisingly, the iron chelators 1,10-phenanthroline (100 µM) and deferoxamine (DFO, 
100 µM) significantly increased secreted PLGF compared to DMSO vehicle control (1.28 ± 0.08 
fold of DMSO and 1.32 ± 0.06 fold of DMSO, respectively; Fig. 5). DFO is a hypoxia mimetic 
agent. Therefore, and considering the close physical proximity of arteriogenesis to regions of 
tissue hypoxia in the coronary circulation, we next assessed the effects of hypoxia on PLGF 
expression in the coculture model. Cocultures containing either scRNA or siHO-1 treated 
endothelial cells were incubated in 1% O2 for 24 h. Hypoxia exposure significantly increased 
PLGF protein concentrations in culture media of negative control treated cocultures relative to the 
normoxic control group (Fig. 6A) but not in the siHO-1 treated group, demonstrating that this 
increase was dependent on endothelial HO-1 expression (Fig. 6A). HO-1 knockdown was 
confirmed by real time PCR. Interestingly, hypoxia significantly decreased HO-1 expression in 
endothelial cells (Fig. 6B, 0.53 ± 0.05 fold of normoxic control). In smooth muscle cells (Fig. 
6C), hypoxia significantly induced HO-1 expression in both the scRNA (4.40 ± 0.42 fold of 
control) and siHO-1 (5.50 ± 0.52 fold of control) treated groups. In contrast to these findings, 
incubating cocultures for the shorter period of 2 h in 1% O2 potently induced HO-1 expression in 
both endothelial cells (Fig. 7A, 1.53 ± 0.11 fold of control) and smooth muscle cells (Fig. 7B, 
4.85 ± 0.68 fold of control). FAC (100 µg/mL, 2 h) induced HO-1 mRNA in both endothelial 







 In this study we demonstrated that FSS increases HO-1 expression both in an in vitro 
coculture model of the cell wall and ex vivo in intact vessels. We further showed that the FSS 
mediated increase in PLGF expression which we previously reported is dependent on HO-1 
activity, and identified endothelial cell HO-1 activity as necessary for this response. FSS-
independent activation of HO-1 (by hemin) was sufficient to induce PLGF expression. Treatment 
of vascular cell cocultures with the three products of HO-1 activity identified iron as a possible 
mediator of the effects of HO-1 on PLGF expression. Paradoxically, chelation of iron by either 
deferoxamine or 1,10-phenanthroline resulted in a similar increase in PLGF expression. Finally, 
we demonstrated that hypoxia also induces PLGF expression, and that this induction was 
dependent on endothelial HO-1 expression, indicating that both FSS and hypoxia can upregulate 
PLGF via a common pathway.   
 Blood flow recovery in the ischemic hindlimb of HO-1 knockout mice is significantly 
impaired
290
 and inhibition of HO-1 activity following hindlimb ischemia in mice results in poor 
flow recovery and diminished recruitment of circulating cells to the ischemic hindlimb
286
. 
Consistent with these observations, we found that inhibition of HO-1 activity attenuates the 
effects of shear stress on PLGF. PLGF stimulates collateral remodeling by recruitment of 
monocytes
10
 and other circulating cells to the vessel wall
291
. Therefore, our findings suggest a 
novel mechanism for the above-described effects of HO-1 inhibition on arteriogenesis in rodent 
models. Conversely to the effects of HO-1 inhibition, stimulation of HO-1 with cobalt 
protoporphyrin IX following myocardial infarction has been shown to result in improved outcome 
and greater neovascularization in rats
292
. Likewise, overexpression of HO-1 in both mice and rats 
results in improved re-establishment of blood flow following hindlimb ischemia 
293, 294
. Similarly, 
overexpression of PLGF has been shown to improve cardiac performance and vascularization 





We report that arteriogenic FSS increases HO-1 expression in endothelial cells and 
smooth muscle cells, consistent with a previous report that laminar FSS induces HO-1 in 
endothelial cells
295
. Increased flow induced HO-1 more robustly in intact vessels than did 
increased shear in our in vitro model. The coculture model much more closely approximates the 
vessel wall than do monocultures of vascular cells
296
. However, there are limitations to the model, 
including the lack of exposure of the cells to cyclic tangential or circumferential stretch. 
Furthermore, the model lacks the complexity of the in vivo extracellular matrix, including the 
extensive glycocalyx of intact vessels (which is important in the mechanosensing machinery of 
the vessel wall)
96, 297-299
. Despite these shortcomings, the coculture model offers practical 
advantages with regard to cell type specificity for both genetic manipulation and assays, which 
are not easily achieved in whole tissue.  
 HO-1 catabolizes heme into three products: biliverdin, CO, and divalent iron. Biliverdin 
is subsequently metabolized into bilirubin by biliverdin reductase. Biliverdin exhibits strong 
antioxidant effects
300-302
 and has been demonstrated to inhibit ROS-induced angiogenesis in tumor 
cells
303
. Furthermore, biliverdin inhibits neointimal thickening following vascular injury in rats
304
. 
These beneficial effects have been attributed to biliverdin’s antioxidant properties. We previously 
demonstrated that the effects of shear stress on PLGF expression are mediated by hydrogen 
peroxide produced by endothelial NADPH oxidase 4. Bilirubin is also a feedback inhibitor of 
HO-1
305
. Consistent with its antioxidant action and its ability to inhibit HO-1, we found that 
biliverdin inhibited rather than enhanced PLGF expression in static cocultures. 
Several studies have demonstrated a cytoprotective role of HO-1
306, 307
. The 
cytoprotective effects of HO-1 have been attributed to CO. Rats pretreated with the CO donor 
methylene chloride before myocardial infarction developed more intermediate and large collateral 
arteries in the infarct area
292
. Furthermore, CO has been reported to induce VEGF expression in 
endothelial cells
308
 and smooth muscle cells
309
. Despite these arteriogenic effects, the CO donor 
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CORM-A2 did not induce PLGF expression in our coculture model, but slightly but significantly 
reduced it instead. CO has also been shown to have antioxidant properties
310-312
. These properties 
may act to reduce PLGF expression. 
 HO-1 activity results in the release of labile iron, which  is cytotoxic. Increased labile 
iron leads to oxidative stress within the cell through Fenton reactions. As a protective response 
against pro-oxidant Fenton reactions, increased labile iron induces an increase in ferritin 
translation
313
 and iron sequestration. Labile iron also induces expression of an iron efflux pump 
colocalized with HO-1
314
. Ferroportin 1, an iron exporter, is also upregulated by labile iron 
generated by HO-1
315
. Indeed, HO-1 knockout in mice and HO-1 deficiency in humans is linked 
to anemia, due to accumulation of iron in tissues and decreased iron recycling
278, 280, 316
, whereas 
overexpression of HO-1 is associated with increased cellular iron efflux and decreased influx 
317
. 
Both hypoxia and FAC have also been reported to increase ferritin synthesis
318
 and ferroportin 
expression
319, 320
. Taken together, these data suggest that an increase in HO-1 expression/activity 
would be expected to result in a decrease in labile or “chelatable” iron. In agreement with this 
idea, we found that chelating iron with either deferoxamine or 1,10-phenanthroline induced rather 
than inhibited PLGF expression. In agreement with this observation, others have reported that 






Following myocardial infarction, collateral vessel remodeling occurs close to and within 
tissues that are ischemic (in contrast to peripheral artery disease, in which remodeling often 
occurs at a significant distance from the most ischemic regions). One of the hallmarks of ischemia 
is the stabilization and activation of hypoxia inducible factor (HIF). HIF1α is capable of 
increasing several arteriogenic cytokines, and its expression is increased during collateral 
development
323-325
. Interestingly, several single nucleotide polymorphisms that result in reduced 





monocytes collected from patients with either good or poor collateralization (based on Rentrop 
score) found a strong positive correlation between HIF1α expression and collateral 
development
328
. We previously reported that hypoxia increases PLGF expression in endothelial 
monocultures
250
. Likewise, in the present study, incubating vascular cell cocultures in 1% O2 for 
24 h resulted in a significant increase in secreted PLGF. Knockdown of endothelial HO-1 resulted 
in an attenuation of this effect, but real time PCR revealed HO-1 mRNA to be significantly 
decreased in the negative control group compared to the normoxic control group. Interestingly, 2 
h exposure to hypoxia significantly increased HO-1 mRNA. This finding suggests that HO-1 may 
play an early role in the regulation of PLGF by hypoxia. 
In conclusion, we demonstrate that the key arteriogenic factor PLGF is regulated by HO-
1 during in response to the physiological stimuli of FSS and hypoxia, both of which are 
considered to be important signals for collateral development in the coronary circulation. This 
study builds on the increased interest in HO-1 and its metabolites in vascular remodeling by 
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Figure. 1 FSS increases HO-1 expression.  Endothelial/smooth muscle cocultures were exposed 
to FSS for 2h and samples collected immediately after exposure, 4h later and 10h later. (A) In 
endothelial cells FSS increased HO-1 mRNA compared to static control at 0h (1.40 ± 0.08) and at 
4h (1.54 ± 0.18) but not at 10h (n=5, p<0.05). (B) In smooth muscle cells cocultured with 
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endothelial cells exposed to FSS HO-1 mRNA was increased at 4h (1.29 ±0.11 fold of static) and 
10h (1.41 ± 0.13 fold of static) (n=5, p<0.05). (C) In mesentery arterioles perfusion at a pressure 

















Figure. 2 HO-1 activity is necessary for FSS to increase PLGF expression. (A) In cocultures 
exposed to FSS ZPP (30 µM) inhibited the increase in secreted PLGF observed in coculture 
exposed to FSS and treated with DMSO (n= 5, p<0.05). (B) In mesentery arterioles perfusion at a 
pressure gradient of 50 mmHg for 2h increased PLGF mRNA compared to 20 mmHg (4.47 ± 





Figure 3. Endothelial HO-1 is necessary for FSS to increase PLGF expression. siRNA 
knockdown was performed on either endothelial cell or smooth muscle cells of cocultures. (A) 
knockdown of HO-1 in endothelial cells attenuated the effects of FSS on PLGF (n=5, p<0.05). 
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(B) FSS increased secreted PLGF in   Knockdown of HO-1 in smooth muscle cells did not alter 
FSS effects on secreted PLGF (n=5, p<0.05). (C) HO-1 knockdown in endothelial cells 
significantly decreased HO-1 mRNA (n=5, p<0.05). (D and E) HO-1 knockdown in either cell 
type had no effect on HO-1 expression in the corresponding cocultured cells  smooth muscle cells 
had not effect on HO-1 expression in endothelial cells (n=5). (C) HO-1 knockdown in smooth 










Figure 4. HO-1 activity increases secreted PLGF. Cocultures were treated for 24h with (A) 
hemin an inducer of HO-1 activity significantly increased secreted PLGF at all concentrations 
used (n=5, p<0.05). (B) Biliverdin significantly decreased secreted PLGF at 100 µM 0.70 ± 0.06 
(n=5, p<0.05).  (C) CORM-A1 significantly decreased secreted PLGF at 200 µM 0.90 ± 0.03 and 
400 µM 0.86 ± 0.02  (n=5, p<0.05). (D) FAS had no significant effect on secreted PLGF. (E) 







Figure 5. Iron chelation increases secreted PLGF. Treating the Cocultures with either the 
divalent iron chelators 1,10-phenanthroline 1.28 ± 0.08 (phen) (100 µM) or the trivalent iron 
chelator deferoxamine 1.32 ± 0.06 (DFO) (100 µM) significantly increased secreted PLGF 





Figure 6. Hypoxia increases secreted PLGF and is dependent on Endothelial HO-1. 
Cocultures were incubated in 1% O2 for 24h. (A) hypoxia significantly increased secreted PLGF 
after 24h (4.74 ± 0.25) this effect was attenuated by HO-1 knockdown in the endothelial cells. 
(n=5, P<0.05) (B) In endothelial cells hypoxia significantly reduced HO-1 mRNA after 24h (0.53 
± 0.05). siRNA knockdown of HO-1 reduced HO-1 mRNA further (0.01 ± 0.00). (n=5, P<0.05) 
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(C) Hypoxia significantly increased HO-1 mRNA in smooth muscle cells (4.40 ± 0.42) and was 


















Figure 7. Both FAC and Hypoxia increase HO-1 mRNA after 2h. Treating cocultures with 
either 1% O2 or FAC (100 µg/ml) for 2h resulted in an significant increase in HO-1 in (A) 
endothelial cells (1.53 ± 0.11) and (1.79 ± 0.08) respectively (n=-5, p<0.05). (B) in smooth 
muscle cells both hypoxia (4.85 ± 0.68 fold of control) and FAC (11.67 ± 2.54) significantly 
























Placental growth factor (PLGF) and vascular endothelial growth factor-A (VEGF-A) are 
important regulators of both physiological and pathological vascular remodeling. We previously 
reported that monocultured human coronary EC primarily express PLGF, while monocultured 
human coronary smooth muscle cells (SMC) primarily express VEGF-A. However, in the 
vasculature, EC and SMC are in close proximity to each other. Thus, in this study we sought to 1) 
determine whether this cell specific expression pattern is maintained when EC and SMC are 
cocultured, and 2) test the hypothesis that EC VEGF-A and/or PLGF production influences SMC 
VEGF-A and/or PLGF expression (and vice versa). EC and SMC were cultured on either side of 
a porous Transwell insert and media PLGF and VEGF-A levels were measured by ELISA. We 
confirmed that the cell type specific PLGF and VEGF-A expression we observed in monocultures 
remains evident in the coculture model. Interestingly, coculture of EC and SMC increased media 
PLGF relative to EC monoculture (38.38 ± 4.17 pg/µg total protein vs 63.78 ± 1.82 pg/µg total 
protein; n=5, p<0.01), but decreased media VEGF-A compared to SMC monoculture(38.90 ± 
2.98 pg/µg total protein vs 228.13 ± 9.57 pg/µg total protein; n=5, p<0.001). Both VEGF-A and 
VEGF-E (VEGFR-2 specific Ligand) increased PLGF in EC monolayers (1.30 ± 0.06 fold of 
control; n=5, p<0.01). In SMC monolayers, the VEGFR-1 ligand PLGF reduced media VEGF-
A(0.81 ± 0.04 fold of control; n=5 p<0.01), while the VEGFR-2 ligand VEGF-E had no 
significant effect on VEGF-A.  Knockdown of PLGF in SMC increased VEGF-A production by 
SMC (1.63 ± 0.05 fold; n=5, p<0.01) , while knockdown of VEGF-A in EC decreased PLGF 
production by EC (0.54 ± 0.02 fold of control; n=5 p<0.001). Coculture conditions increased 
VEGFR-2 levels on the surface of EC, but decreased VEGFR-1 levels on the surface of SMC. 
Inhibition of VEGFR-2 tyrosine kinase activity decreased PLGF and increased VEGF in EC and 
in cocultures, but had no effect these parameters in SMC. We conclude that PLGF and VEGF-A 
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exert both paracrine and autocrine regulatory effects on each other and that these effects are 
partially mediated by VEGFR-2. 
Introduction 
Despite advances in pharmacological interventions, ischemic cardiovascular disease remains a 
leading cause of death in the United States
1
 and is likely to remain so with the increased 
incidence of metabolic syndrome and diabetes, which favor the development of ischemic 
cardiovascular disease. In the coronary circulation, as atherosclerosis progresses, the development 
of a flow limiting stenosis leads to a drop in blood pressure downstream of the stenosed region. 
This decrease in pressure results in an increased pressure gradient across any anastomoses that 
connect the area of low pressure to an area of higher pressure, leading to increased flow through 
these vessels. If the increased flow persists, these collateral vessels remodel in an outward 
direction, such that their caliber and wall thickness increase to accommodate the higher flow rate. 
Collateral remodeling can reestablish flow to tissue downstream of the occlusion and alleviate 
ischemia. In the coronary circulation, the presence of native collaterals and the extent to which 
these remodel following an ischemic event is a direct predictor of survival
2, 3
. There is significant 
variability in the development of coronary collaterals in the human heart
4
 and disease states such 
as type II diabetes are associated with a poor remodeling response. Therefore, treatments that 
could enhance collateral remodeling would be very useful clinically and could increase the 
survival of patients with coronary artery disease
5
. A more in-depth understanding of the 
mechanisms that govern collateral remodeling is needed before the development of 
pharmaceutical agents capable of stimulating it becomes possible. 
Vascular endothelial growth factor-A (VEGF-A) is the archetypal member of the VEGF 
family of growth factors and is a ligand for the tyrosine kinase VEGF receptors 1 and 2 
(VEGFR1, VEGFR2) and neuropilin-1
6-9
. VEGF-A plays an important role in the development of 
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the vasculature during embryogenesis and during both physiological and pathological vascular 
remodeling later in life 
10
. Mice underexpressing VEGF-A exhibit a decrease in the number of 
preexisting collateral vessels, whereas mice overexpressing VEGF-A have a higher density of 
preexisting collateral vessels
11
. As a result, the former model demonstrates diminished 
arteriogenesis in response to hindlimb ischemia, while the latter demonstrates increased 
arteriogenesis. Placental growth factor (PLGF) is another member of the VEGF family, which 
only signals through VEGFR1
12, 13
. PLGF expression is necessary for collateral remodeling, and 
mice lacking PLGF exhibit impaired reestablishment of flow following femoral ligation
14
. PLGF 
is chemotactic for monocytes, which express VEGFR1 but not VEGFR2
15
. It is through the 
recruitment of monocytes that PLGF stimulates collateral remodeling
14
. Interestingly, PLGF 
binding to VEGFR1 elicits a downstream response distinct from the response that occurs when 
VEGF-A binds to VEGFR1
16
, and despite the similarity in the structure of the two cytokines, they 
are not interchangeable and exhibit different physiological effects 
14, 16-18
. Following femoral 
ligation in mice, exogenous VEGF-A stimulates sprouting of capillaries and increases branching 
of collateral vessels in the hindlimb; PLGF, on the other hand, stimulates enlargement of 
preexisting collaterals 
14, 17
. In clinical trials, therapies focusing on one particular growth factor 
have fallen short of their intended goals 
3
. Collateral remodeling is a complex process involving 
multiple chemokines and cytokines, and an understanding of the interactions between these 
factors is required in order to reveal the underlying mechanisms governing the remodeling 
process.  
We previously reported that endothelial cells are the predominant source of PLGF in the 
vessel wall and that smooth muscle cells are the predominant source of VEGF-A
19
. Recently, we 
demonstrated that increased fluid shear stress increases PLGF expression in an endothelial 
cell/vascular smooth muscle cell coculture model
20
. We also showed that coculturing endothelial 
cells with smooth cells significantly increases the concentration of PLGF in media, compared to 
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media from endothelial monocultures, suggesting that PLGF production is influenced by cell-cell 
interactions. In this study, we sought to determine the autocrine and paracrine effects of PLGF 
and VEGF-A on each other, and to determine whether VEGF receptor expression is also 
modulated by coculture conditions. 
 
Materials and Methods 
Reagents 
Human recombinant VEGF-A and PLGF were purchased from R&D Systems 
(Minneapolis, MN). VEGF-E was purchased from Prospec (East Brunswick, NJ). The VEGFR-2 
tyrosine kinase inhibitor SU 1498 was purchased from Cayman Chemicals (Ann Arbor, MI). All 
other reagents were purchased from Sigma Aldrich (St. Louis, MO) unless stated otherwise. 
Cell culture 
Primary human coronary artery endothelial cells (HCAEC) and smooth muscle cells 
(HCASMC) were purchased from Lonza (Walkersville, MD). Cells were grown in 5% CO2 in a 
humidified incubator at 37°C. HCASMC were grown in smooth muscle basal medium (SmBM, 
Lonza) supplemented with a smooth muscle growth medium kit (SmGm2, Lonza). The cell 
donors were a 56 year old female and a 30 year old male. HCAEC were grown in endothelial 
basal medium (EBM, Lonza) supplemented with an endothelial growth medium kit (EGM-2MV, 
Lonza). The cell donors were a 21 year old male and a 30 year old male. All experiments were 
carried out between passage 4 and 6. 
Endothelial cell/smooth muscle cell cocultures were established as we previously 
described
20
. Briefly, Corning costar (Corning, NY) 24mm TRANSWELL® polyester membrane 
inserts with a 0.4 µM pore size were inverted and coated with 0.1% Gelatin diluted in growth 
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medium. Inserts were incubated for 1 h at 37°C in a humidified incubator. Gelatin was aspirated 
off the insert and HCASMC were seeded onto the inverted inserts (~10
5
cells/insert) and incubated 
for 4 hours in 5% CO2 at 37°C in a humidified incubator. Inserts were then inverted into 6 well 
plates containing growth medium and incubated for 48 h. 0.1% Gelatin diluted in growth medium 
was added to the apical side of the membrane and incubated as above for 1 h following the gelatin 
was aspirated and HCAEC (2x10
5
cells/insert) seeded on the apical side of the insert and 
incubated as above for 24 h. cocultures were subjectively checked for confluence. All 
experiments monoculture and coculture were carried out at 80% - 90% confluence. Prior to 
experiments culture medium was replaced for 2% serum medium for 24 h. 2% Serum medium 
was made by diluting the corresponding medium in Dulbecco’s Modified Eagle’s Medium 
(DMEM) Hyclone (Pittsburgh, PA). 
 Real Time PCR 
Cells were rinsed with 37°C PBS (Hyclone), then incubated in TrypLE Express (Gibco, 
Waltham, MA) for 5 minutes at 37°C. Following cell detachment, 2 volumes of complete 
medium were added to the cells and the cell suspension was centrifuged at 300g for 5 minutes. 
Total RNA was isolated from the pellet using RNeasy Mini columns (Qiagen, Valencia, CA) per 
manufacturer’s instructions. The concentration and quality of the RNA was determined using a 
Take 3 plate in a Synergy HT multimode plate reader (BioTek, Winooski, VT). Both genomic 
DNA removal and cDNA synthesis were carried out using the QuantiTect reverse transcription 
kit (Qiagen). Real time PCR reactions were carried out in a ABI 7500 Fast instrument (Applied 
Biosystems, Carlsbad, CA) using PerfeCTa SYBR Green FastMix, Low ROX (Quanta 
Biosystems, Gaithersburg, MD). Primers were designed using Primer Express software and 
custom-synthesized by Invitrogen (Carlsbad, CA). Primer sequences were as previously 
described
19, 21
. To avoid confounding effects of housekeeping gene selection when making 
comparisons between different cell types, PLGF and VEGF-A mRNA expression was normalized 
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to the geometric average of the housekeeping genes β-actin and GAPDH, and relative gene 
expression was quantified using the ΔΔCt method. 
ELISA 
 Secreted PLGF and VEGF-A concentrations in culture media were determined using the 
human PLGF and VEGF-A DuoSet ELISA development kits (R&D Systems, Minneapolis, MN) 
according to manufacturer’s protocol. Data were normalized to total protein concentration, as 
determined by BCA assay (Pierce, Rockford, IL). Samples were treated with protease inhibitor 
cocktail (1 mM PMSF, 1 mM Na3VO4, 1 µg/ml leupeptin, 1 mM benzamidine-HCl, 1µg/ml 
aprotinin, 1µg/ml pepstatin A) prior to analysis. 
Flow cytometry  
 To measure the cell surface expression of VEGFR1 and VEGFR2, cells were collected as 
above and resuspended in PBS containing 1% BSA, then incubated for 45 minutes at room 
temperature in the dark with a 1:500 dilution of both Dylight 650-conjugated rabbit anti-human 
VEGFR1 polyclonal antibody (NB100527, Novus Biologicals, San Diego, CA) and Dylight 488-
conjugated rabbit anti-human VEGFR2 polyclonal antibody (NB1002382G, Novus Biologicals). 
After incubation, labeled cells were resuspended in 1% BSA-PBS and the mean fluorescence 
intensity (MFI) was determined by flow cytometry (Accuri C6, Ann Arbor, MI). 
Transfection 
 Cells were transfected using Lipofectamine RNAiMAX (Invitrogen) following 
manufacturer’s instructions. Five nM siRNA was precomplexed with Lipofectamine RNAiMAX 
for 20 min in Opti-MEM media (Gibco), after which 4 volumes of DMEM (Hyclone) containing 
10% FBS (Gibco) were added, making complete transfection medium. siRNA consisting of the 
following sequences was used to knock down PLGF: sense, 5’-AGGUGGAAGUGGUACCCUU-
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3’, overhang dTdT; antisense, 5’-AAGGGUACCACUUCCACCU-3’, overhang, dCdT 
(Invitrogen). For VEGF-A knockdown, a predesigned siRNA was used (Silencer Select s460, 
Invitrogen). Silencer Select negative control no.1 siRNA (Invitrogen) was used as a negative 
control. Cells were seeded into 6 well plates and grown to 90% confluence, after which cells were 
rinsed and the medium replaced with transfection medium. After 6 h in transfection medium, the 
cells were switched to 2% serum medium for a further 24h. For cell specific knockdown in 
cocultures, HCASMC were transfected directly on the insert prior to addition of HCAEC, 
whereas HCAEC were trypsinized immediately after transfection and seeded onto the apical side 
of the insert. Effectiveness of the siRNA treatment was determined by real time PCR, as outlined 
above. 
Statistical analysis 
All data are presented as mean ± SEM. Experiments were replicated at least five times. 
Data were analyzed by either student’s T-test, or one-way ANOVA followed by Tukey’s range 
test, as appropriate. The level of significance was set at p<0.05.  
Results 
Consistent with our previously reported results
19
, we found that monocultured HCAEC 
predominantly expressed PLGF (PLGF, 38.38 ± 4.17 pg/µg total protein; VEGF-A, 5.28 ± 1.73 
pg/µg total protein), whereas monocultured HCASMC predominantly expressed VEGF-A 
(PLGF, below detection limit; VEGF-A, 228.13 ± 9.57 pg/µg total protein; Fig.1A and B). 
Interestingly, coculture of HCAEC and HCASMC significantly increased the PLGF protein 
concentration in media (63.78 ± 1.82 pg/µg total protein), compared to media from HCAEC 
monocultures (Fig. 1A, p<0.01). The opposite effect of coculture was observed for VEGF-A, 
which was significantly lower in coculture media (38.90 ± 2.98 pg/µg total protein) compared to 
media from HCASMC monocultures (Fig. 1B, p<0.001). Consistent with the protein analysis, 
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PLGF mRNA was significantly higher under coculture conditions in both HCAEC (2.14 ± 0.26 
fold of monoculture; p<0.01 Fig. 1C) and HCASMC (1.78 ± 0.10 fold of monoculture, p<0.01; 
Fig. 1D). Coculture also significantly increased VEGF mRNA in HCAEC (1.67 ± 0.22 fold of 
monoculture) (Fig. 1E, p<0.05), but had no effect on VEGF-A mRNA in HCASMC (Fig. 1F). 
We hypothesized that HCASMC-derived VEGF-A could contribute to the increased 
production of PLGF by HCAEC in cocultures. Therefore, we next tested the effect of 
supplementing HCAEC monocultures with exogenous VEGF-A (100 ng/mL). VEGF-A 
significantly increased the concentration of PLGF in culture media (1.72 ± 0.05 fold of control) 
(Fig. 2A). Treatment of HCAEC with the VEGFR-2 specific ligand VEGF-E (100 ng/mL) (Fig. 
2) also significantly increase secreted PLGF (1.30 ± 0.06 fold of control; p<0.01). Likewise, we 
hypothesized that HCAEC-derived PLGF could influence VEGF-A production by SMC. 
Treatment of HCASMC with PLGF, a VEGFR-1 specific ligand (100 ng/mL) significantly 
reduced media VEGF-A (0.81 ± 0.04 fold of control; p<0.01). In contrast, the VEGFR-2 ligand 
VEGF-E (100 ng/mL) had no significant effect on HCASMC media VEGF-A (Fig. 2B). 
We next tested the effect of knocking down endogenous VEGF-A and PLGF on the 
levels of these cytokines. In HCAEC monocultures, knockdown of VEGF-A significantly 
decreased media PLGF (0.54 ± 0.02 fold of control; p<0.001; Fig. 3A). Supplementing media 
with VEGF-A (100 ng/mL) concurrently with VEGF knockdown rescued media PLGF, and led to 
a significant increase in media PLGF compared to control (1.28 ± 0.03 fold of control; p<0.001; 
Fig. 3A).  However, knockdown of VEGF-A in HCAEC had no significant effect on PLGF 
mRNA (Fig. 3B). VEGF-A knockdown was confirmed by real time PCR (Fig. 3C). In HCASMC 
monocultures, knockdown of PLGF significantly increased media VEGF-A, compared to control 
(1.63 ± 0.05 fold; p<0.01; Fig. 4A). PLGF knockdown was confirmed by real time PCR (Fig. 4B) 
PLGF knockdown also significantly increased VEGF-A mRNA (3.84 ± 0.83 fold of control; n=5, 
p<0.05; Fig. 4C).  
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VEGFR-2 activation (with VEGF-E) increases PLGF production by HCAEC 
monocultures, and PLGF levels are also increased by HCAEC/HCASMC coculture. In contrast, 
VEGFR-1 activation (with PLGF) decreases VEGF-A production by HCASMC, and VEGF-A 
levels are also decreased by HCAEC/HCASMC coculture. Therefore, we hypothesized that 
coculture could be affecting the surface expression of VEGFR-1 and VEGFR-2. In HCAEC, 
consistent with the results reported above, coculture significantly increased surface VEGFR-2 
expression (Fig. 5B; 1.36 ± 0.07 fold MFI; p<0.05), but had no significant effect on VEGFR-1 
surface expression (Fig. 5A). In HCASMC, also consistent with the above-described results, 
coculture significantly decreased VEGFR-1 surface expression (Fig. 5C; 0.74 ± 0.02 fold MFI; 
p<0.001), with no significant effect on surface VEGFR-2 expression (Fig. 5D). 
To further assess the role of VEGFR-2 in regulating PLGF and VEGF-A, we treated both 
monocultures and cocultures with the VEGFR-2 specific tyrosine kinase inhibitor SU1498 (10 
nM). Inhibition of VEGFR-2 tyrosine kinase activity significantly decreased media PLGF protein 
in HCAEC (Fig. 6A; 0.60 ± 0.02 fold of HCAEC monoculture; p<0.001) and in cocultures (4.81 
± 0.22 vs 1.80 ± 0.09 fold of HCAEC monoculture), in agreement with our other findings 
suggesting a positive role for VEGFR-2 signaling in regulation of PLGF. PLGF was not detected 
in SMC monoculture media either with or without SU1498 treatment (Fig. 6A). Interestingly, 
SU1498 also significantly increased media VEGF-A in HCAEC (Fig. 6B; 3.15 ± 0.39 fold of 
HCAEC monoculture; p<0.05), and to a lesser extent in cocultures. Consistent with our findings 
suggesting that VEGFR-1, but not VEGFR-2, contributes to regulation of VEGF-A in HCASMC, 






Coculturing HCAEC with HCASMC resulted in a significant increase in PLGF protein in 
culture media (as compared to media from HCAEC monocultures). HCAEC produced much 
more PLGF than HCASMC, consistent with previous reports by our group
20
. Along with 
increased PLGF protein, coculture resulted in a significant increase in PLGF mRNA in both 
HCAEC and HCASMC, suggesting that the increase in PLGF protein with coculture is at least 
partly due to increased gene transcription. These findings suggest that it is likely that PLGF 
production by endothelial cells in vivo is underestimated by in vitro studies of endothelial cell 
monocultures. Furthermore, PLGF levels may be reduced in vessels in which EC/SMC contact 
and/or communication is dysfunctional due to disease or injury, relative to expression in healthy 
quiescent vessels.  
Coculture of HCAEC and HCASMC resulted in a significant reduction in VEGF-A 
protein in media. This effect occurred without a significant effect of coculture on VEGF mRNA 
in HCASMC, and with a significant increase in VEGF mRNA in HCAEC. The most likely 
explanation for the reduction in VEGF-A protein without a corresponding effect on VEGF-A 
mRNA in HCASMC (the primary source of VEGF-A in the coculture model) is that VEGF-A is 
being rapidly removed from the media by endothelial cell VEGF receptor binding and uptake. 
Indeed, we previously demonstrated that VEGF-A decreases in the presence of endothelial cells
19
, 
while others have demonstrated active uptake (endocytosis) of VEGF-A by endothelial cells via 
VEGFR-2
22
 and other pathways which lead to nuclear accumulation
23, 24
. In agreement with this 
possibility, we found that coculture resulted in an increase in HCAEC cell surface VEGFR-2 
levels. Another mechanism that may contribute to the effects observed is the post transcriptional 
regulation of VEGF expression. Coculturing endothelial cells and smooth muscle cells has been 
demonstrated to result in the trafficking of miRNA from endothelial cells to smooth muscle cells 
via micro-particles
25, 26





. Although VEGF-A mRNA increased with coculture in HCAEC, HCAEC are a 
relatively minor source of VEGF-A in the coculture system and thus this effect on overall VEGF-
A protein levels was negligible. 
Exogenous VEGF-A has been shown to upregulate PLGF production in several primary 
endothelial cell lines 
28, 29
. In the present study, we found that exogenous VEGF-A and VEGF-E, 
similarly increased PLGF production in HCAEC. VEGF-E exclusively binds VEGFR-2, while 
VEGF-A binds both VEGFR-1 and VEGFR-2. These data suggest the effects VEGF-A are 
mediated by VEGFR-2. Knockdown of VEGF-A resulted in a significant reduction in media 
PLGF. This is consistent with the in vivo reduction of PLGF expression that has been reported in 
mice treated with VEGF-A neutralizing antibodies
29
. The concurrent treatment with exogenous 
VEGF-A and knockdown of VEGF-A not only rescued the reduction in media PLGF but 
significantly increased media PLGF demonstrating the effects of knockdown are specific to a lack 
of VEGF-A.  
Treating HCASMC with exogenous PLGF resulted in a significant decrease in VEGF-A 
protein in culture media, whereas knockdown of PLGF in HCASMC significantly increased both 
VEGF-A protein and mRNA. PLGF exclusively signals through VEGFR-1
12, 13
. Homozygous 
VEGFR-1 knockout is embryonically lethal in mice, and disorganized vasculature resulting from 
uncontrolled endothelial overgrowth is the primary defect causing lethality
30
. This suggests that 
PLGF is a negative regulator of endothelial proliferation through VEGFR-1 signaling. PLGF has 
been demonstrated to induce vascular normalization and decrease sprouting
31
, whereas blocking 
VEGFR-1 results in increased angiogenesis in adipose tissue
32
. Similarly, several studies have 
demonstrated the inhibition of VEGF-A induced angiogenesis by PLGF
33-37
. Consistent with 
these findings, we demonstrate that both exogenous and endogenous PLGF acts as negative 
regulator of VEGF-A in HCASMC. 
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Blocking VEGFR-2 in vivo attenuates the VEGF-A induced increase in PLGF
38
. In 
keeping with these previously reported results, we found that inhibiting VEGFR-2 tyrosine kinase 
activity with the small molecule inhibitor SU1498 decreased PLGF protein in both HCAEC 
monocultures and in cocultures. Interestingly, VEGF-A protein was increased by SU1498 in both 
HCAEC monocultures and in cocultures. No significant effect of VEGFR-2 inhibition on PLGF 
or VEGF-A expression was observed in HCASMC. This cell type specific effect may be related 
to the fact that VEGF-induced PLGF expression is dependent on ERK phosphorylation
38
, and 
VEGFR-2 activation has differential effects on ERK in EC and SMC. Studies with the VEGFR-2 
inhibitor SU1498 demonstrated that VEGFR-2 inhibition decreases phospho-ERK activity in 
human aortic endothelial cells 
39
, but not in human aortic smooth muscle cells
39
. In addition, our 
results suggest that VEGFR-1 plays a more important role in regulating VEGF-A production by 
HCASMC than does VEGFR-2. 
We observed that HCASMC cocultured with HCAEC exhibited decreased cell surface 
VEGFR-1 expression, compared to HCASMC monocultures. This finding is similar to results 
reported in models of vascular injury. Smooth muscle VEGFR-1 is increased in rat carotid 
arteries following balloon injury 
40
. Likewise, wire injury of mouse carotid arteries increases 
smooth muscle VEGFR-1 expression
41
. Our data and these reports are consistent with an 
inhibitory effect of EC/SMC communication on VEGFR-1 expression. 
Coculturing HCAEC with HCASMC significantly increased VEGFR-2 in HCAEC. 
Several studies have demonstrated the role of VEGFR-2 in mechanosensing of fluid shear stress. 
VEGFR-2 tyrosine kinase activity is required for fluid shear stress induced activation of eNOS 
and vasodilation
42
. Likewise, fluid shear stress increases VEGFR-2 phosphorylation, and 
inhibiting VEGFR-2 tyrosine kinase activity attenuates the anti-apoptotic effects of fluid shear 
stress
43
. Consistent with these findings, we previously reported that coculturing HCAEC with 
HCASMC results in an increase in sensitivity to fluid shear stress. 
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In conclusion, the results of this study demonstrate that crosstalk between vascular 
smooth muscle cells and endothelial cells regulates the expression of both PLGF and VEGF-A. 
These findings suggest that cocultures of these two cell types better recapitulate the signaling 
environment of stable quiescent the coculture model a useful tool in studying vascular 
physiology. Considering that the regulation of PLGF and VEGF-A has overarching implications 
for arteriogenesis, atherosclerosis, and tumor angiogenesis, greater insight into the molecular and 
cellular interactions of these factors vessels than does monocultures, making in the vessel wall 
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Figure 1. PLGF and VEGF expression in EC and SMC monoculture and coculture. (A) 
PLGF protein is predominantly produced by EC and is significantly increased when EC and SMC 
are cocultured (n=5, *p<0.001 compared to EC monoculture). (B) VEGF-A protein is mostly 
produced by SMC, and is decreased when EC and SMC are cocultured (n=5, *p<0.001 compared 
to EC monoculture, †p<0.001 compared to SMC monoculture). Coculture significantly increased 
PLGF mRNA in both EC (C) and SMC (D). Coculture significantly increased VEGF-A mRNA in 




Figure 2. Effect of exogenous VEGFR ligands on VEGF-A and PLGF production in 
monocultures. (A) VEGF-A (100 ng/ml) significantly increased PLGF protein in media 
compared to control (1.72 ± 0.05 fold of control). The VEGFR-2 specific ligand VEGF-E (100 
ng/mL) also significantly increased PLGF protein in HCAEC culture media (1.30 ± 0.06 fold of 
control). (B) The VEGFR-1 ligand PLGF (100 ng/mL) significantly decreased VEGF-A protein 
in HCASMC culture media (0.81 ± 0.04 fold of control), whereas the VEGFR-2 ligand VEGF-E 






Figure 3. Effect of knockdown of VEGF-A in HCAEC monoculture  (A) Knockdown of 
VEGF-A in HCAEC monoculture significantly decreased PLGF protein. Concurrent treatment 
with exogenous VEGF-A rescued PLGF protein expression and led to an increase relative to 
untreated cells. (B) In contrast to its effect on PLGF protein, knockdown of VEGF-A in HCAEC 
monocultures had no significant effect on PLGF mRNA expression. (C) siVEGF reduced VEGF-
A mRNA levels to ~50% of control in HCAEC monocultures (n=5, *p<0.05 compared to both 




Figure 4. Effect of knockdown of PLGF in HCASMC monoculture.  (A) Knockdown of 
PLGF in HCASMC monocultures increased VEGF-A protein in culture media. (B) siPLGF 
decreased PLGF mRNA to ~25% of control in HCASMC monocultures (n=5, *p<0.05 compared 
to both control and siSCR). (C) PLGF knockdown in HCASMC monoculture significantly 




Figure 5. VEGFR-1 and VEGFR-2 expression in EC and SMC monoculture and coculture. 
(A) For VEGFR-1 no difference in MFI was detected between EC in monoculture and coculture. 
(B) MFI was significantly increased for VEGFR-2 in cocultured EC compare to monoculture EC. 
(C) SMC VEGFR-1 was significantly decreased in coculture compare to monoculture. (D) no 
significant change MFI was detected between SMC monoculture and coculture (n=5, *p<0.05 




Figure 6. SU1498 inhibits PLGF expression and induces VEGF expression. (A) SU1498 
significantly reduced PLGF protein in the media of both EC monocultures and cocultures. PLGF 
was below the limit of detection for SMC monocultures. (B) VEGF protein was significantly 
increased in SU1498 treated EC and coculture culture media. No significant difference was 








The overall objective of this study was to delineate the mechanisms regulating PLGF expression 
in the vascular wall during coronary arteriogenesis. Our central hypothesis was that PLGF 
expression in the vessel wall is regulated by fluid shear stress. The rationale for the proposed 
research is that both fluid shear stress and PLGF are integral to collateral growth and an 
understanding of the mechanisms by which fluid shear stress regulates PLGF would provide 
insight into growth factor regulation in general. To test this central hypothesis two specific aims 
were pursued aims: 
1. Characterize the effects of increased fluid shear stress on PLGF expression in 
isolated perfused vessels and in a vascular smooth muscle cell/vascular endothelial 
cell co-culture system. 
2. Characterize the pathway by which increased fluid shear stress regulates PLGF 
expression. 
3. Characterize the effects of coculture on PLGF and VEGF expression. 
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The main findings of this study are that fluid shear stress does indeed regulate PLGF expression. 
These effects of fluid shear stress are mediated by hydrogen peroxide that is most likely Nox4 
derived. HO-1 activity was also shown to be necessary for fluid shear stress to affect PLGF 
expression. We also demonstrated that PLGF and VEGF affect each other’s expression and are 
differentially regulated in coculture.  In this study we identified key regulators of arteriogenesis 
and demonstrate their role in the regulation of PLGF under flow conditions. The overarching 
findings described above further emphasize PLGF as a keystone of arteriogenesis. 
 FSS upregulated PLGF expression in both intact perfused vessels and in the vascular cell 
coculture model, we also demonstrate FSS-induced PLGF expression is dependent on H2O2.. In 
support of this finding and the role for H2O2 in arteriogenesis, increasing O2•− and decreasing 
H2O2 by knocking out endothelial SOD results in diminished collateral remodeling in the mouse 
ischemic hindlimb1. Antioxidant treatment which decreases both O2•− and H2O2 also decreases 
blood flow recovery after femoral artery ligation1-3.  Furthermore, exogenous H2O2 increases 
PLGF expression in HCASMC4, 5. Nox are the only family of enzymes that are dedicated to the 
production of ROS 6. Inhibition of Nox causes a reduction in collateral remodeling in follow 
femoral artery ligation in mice 7 and several in vivo models have demonstrate a role for Nox in 
the remodeling process 3, 8-10. We found Nox4 expression to be increased by FSS agreement 
with previous studies11-13, intracellularly Nox4 is associated with the proteins implicated in 
sensing fluid shear stress14, 15. Nox 4 predominantly produces H2O2  and is constitutively active 
16. In agreement with previous data we found Nox4 to be the predominant isoform in our 
coculture model17, 18.  Flow recovery in Mice over expressing Nox4 in the endothelium 
following hindlimb ischemia is more rapid than wild type controls 10. Conversely, Nox4 
knockout mice show poor recovery of hindlimb perfusion after femoral artery ligation 9. 
Knockdown of Nox4 in the endothelial cells of our coculture model attenuated the effects of 
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shear stress on both PLGF and H2O2, this suggest Nox4 was the source of FSS induced H2O2 
which is necessary for FSS to regulate PLGF expression.  
 We next set out to identify pathways downstream of Nox4 that contribute to the 
regulation of PLGF by FSS. Schroder et. al. suggested that Nox4 produced H2O2 induces the 
nuclear accumulation of NF-E2-related factor 2  (Nrf2) and increased HO-1 expression who’s 
activity facilitates the remodeling process9. The Nrf2 pathway is the major antioxidant response 
to oxidative stress 19. During oxidative stress Nrf2 is freed from keap1 suppression and allowed 
to translocate to the nucleus where it binds to antioxidant response element (ARE) domains in the 
promoter region of multiple antioxidant enzymes including heme oxygenase 1 (HO-1). 
Interestingly, Nrf2 knockout results in improved blood flow recovery in mice following femoral 
artery ligation20, 21 this is likely to be the result of a decrease in Nrf2’s anti-inflammatory 
effects. Contradictory to the hypothesis that Nrf2 plays a beneficial role in collateral remodeling. 
HO-1 on the other hand is up regulated in the hindlimb following femoral artery ligation9, 22. 
The expression of PLGF and HO-1 are both significantly increased in mouse hind limb skeletal 
muscle early on following femoral artery ligation23. FSS induces HO-1 activity and expression in 
endothelial cells and is dependent on Nox derived ROS 11, 24, 25. While HO-1 
haploinsufficiency in mice causes a decrease in PLGF expression and a reduction in 
revascularization following hindlimb ischemia 26. We report that FSS increases HO-1 mRNA 
and that inhibition of HO-1 attenuates the effects of FSS on PLGF. Furthermore, Knockdown of 
HO-1 in the endothelial cells of the coculture model resulted in abrogation of the effect of FSS on 
PLGF. Consistent with these findings and with the role of PLGF in recruiting monocytes to the 
vessel wall27 inhibiting HO-1 in vivo reduces recruitment of circulating cell to the vessel wall 
along with decreased collateral remodeling following femoral ligation22.   
 HO-1 catabolizes heme into three products biliverdin, CO, and divalent iron. Biliverdin 
and CO both caused a decrease in PLGF expression in cocultures. One explanation of these 
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findings is that both these metabolites have antioxidant properties28-30 31-33. This would result 
in a decrease in H2O2 which in turn would be expected to decrease PLGF expression.  
 
Figure 1. Diagram of proposed signaling pathway. (1) FSS increases NOX4 activity and 
H2O2 production. (2) H2O2 induces HO-1 by an unknown mechanism. (3) HO-1 activity 
releases Fe
+2
, which induces Ft, which in turn sequesters iron (4). HO-1 activity also 
increases iron efflux and decreases iron influx (5); these effects result in an overall decrease 
in labile iron. We propose that this decrease upregulates PLGF by activating one or more of 
several possible iron sensitive transcription factors. (6) SMC induce an increase in EC 
VEGFR2 by an unknown mechanism. We hypothesize that this effect increases the 
sensitivity of EC to FSS, promoting upregulation of PLGF by FSS. (7) VEGF from SMC 
increases EC PLGF expression. (EC; endothelial cells, SMC; smooth muscle cells, NOX4; 
NADPH oxidase 4, HO-1; heme oxygenase 1, Ft; ferritin, VEGFR2; VEGF receptor 2). 
 HO-1 activity results in the release of labile iron. Labile iron can cause oxidative stress 
by taking part in Fenton reactions and is tightly regulated in all mammalian cells. The primary 
method is by sequestering iron in ferritin. HO-1 activity also induces an increase in ferritin 
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translation34. HO-1 Activity and increased labile iron have been linked to increased iron efflux 
35-37. In general HO-1 activity can be considered to decrease the amount labile intracellular iron 
by increased efflux and sequestration in ferritin. This decreased iron has been previously 
demonstrated to induce several pro arteriogenic growth factors such as HIF-1α, EGR-1, and 
MTF-1 38-40 of which EGR-141 and MTF-142 have been demonstrated to be transcription 
factors of PLGF. We next provided evidence for a decreased labile iron pool increasing PLGF 
expression by chelating iron with either deferoxamine or 1,10-phenanthroline. Both increased 
PLGF expression. While others report that treatment with DFO results in enhanced flow recovery 
following hindlimb ischemia compared to vehicle treated control in mice 43 and in rabbits44. 
Due to similarities between the effects of fluid shear stress and hypoxia we determined how 
hypoxia affects PLGF expression. Expectedly we found it to also increase PLGF expression we 
also found endothelial HO-1 expression to be necessary for hypoxia to affect PLGF expression. 
Considering the central role of PLGF in arteriogenesis these data suggest HO-1 as common 
pathway for FSS and hypoxia to induce arteriogenesis. 
  We report that PLGF expression is significantly increased in coculture compared to 
HCAEC monoculture. We also report that HCASMC predominant produce VEGF-A. We then 
determined the autocrine and paracrine effects of VEGF-A on PLGF expression and concluded 
that VEGF-A is a positive regulator of PLGF in agreement with previous studies 45, 46. These 
finding would suggest that HCASMC induce an increase in HCAEC PLGF production via 
VEGF-A. Indeed, we found that treating cocultures with a VEGFR-2 inhibitor significantly 
reduced secreted PLGF. We also found cocultured endothelial cells to be more sensitive to FSS 
than monocultured cells. VEGFR-2 is considered to play a role in the mechanosensing of FSS47, 
48. We found cocultured HCAEC to express significantly higher VEFGR-2 which would likely 
increase their sensitivity to FSS. Our finding suggest that there is significant variation between of 





1. Kim HW, Lin A, Guldberg RE, Ushio-Fukai M, Fukai T. Essential role of extracellular 
sod in reparative neovascularization induced by hindlimb ischemia. Circ.Res. 
2007;101:409-419 
2. Ebrahimian TG, Heymes C, You D, Blanc-Brude O, Mees B, Waeckel L, Duriez M, 
Vilar J, Brandes RP, Levy BI, Shah AM, Silvestre JS. Nadph oxidase-derived 
overproduction of reactive oxygen species impairs postischemic neovascularization in 
mice with type 1 diabetes. Am.J.Pathol. 2006;169:719-728 
3. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, Alexander RW. Role 
of gp91phox (nox2)-containing nad(p)h oxidase in angiogenesis in response to hindlimb 
ischemia. Circulation. 2005;111:2347-2355 
4. Shaw JH, Xiang L, Shah A, Yin W, Lloyd PG. Placenta growth factor expression is 
regulated by hydrogen peroxide in vascular smooth muscle cells. American Journal of 
Physiology - Cell Physiology. 2011;300:C349-C355 
5. Shaw JH, Lloyd PG. Post-transcriptional regulation of placenta growth factor mrna by 
hydrogen peroxide. Microvascular Research. 2012;84:155-160 
6. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology 
and pathology. Circulation Research. 2012;111:1091-1106 
7. Rocic P, Kolz C, Reed R, Potter B, Chilian WM. Optimal reactive oxygen species 
concentration and p38 map kinase are required for coronary collateral growth. 
Am.J.Physiol Heart Circ.Physiol. 2007;292:H2729-H2736 
8. Distasi MR, Unthank JL, Miller SJ. Nox2 and p47phox modulate compensatory growth 
of primary collateral arteries. American Journal of Physiology - Heart and Circulatory 
Physiology. 2014 
9. Schröder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike 
P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, Brandes RP. Nox4 is a 
protective reactive oxygen species generating vascular nadph oxidase. Circulation 
Research. 2012;110:1217-1225 
10. Craige SM, Chen K, Pei Y, Li C, Huang X, Chen,  C, Shibata R, Sato K, Walsh K, 
Keaney JF. Nadph oxidase 4 promotes endothelial angiogenesis through endothelial nitric 
oxide synthase activation. Circulation. 2011;124:731-740 
11. De Keulenaer GW, Chappell DC, Ishizaka N, Nerem RM, Alexander RW, Griendling 
KK. Oscillatory and steady laminar shear stress differentially affect human endothelial 
redox state: Role of a superoxide-producing nadh oxidase. Circulation Research. 
1998;82:1094-1101 
12. Duerrschmidt N, Stielow C, Muller G, Pagano PJ, Morawietz H. No-mediated regulation 
of nad(p)h oxidase by laminar shear stress in human endothelial cells. The Journal of 
Physiology. 2006;576:557-567 
13. Bretón-Romero R, González de Orduña C, Romero N, Sánchez-Gómez FJ, de Álvaro C, 
Porras A, Rodríguez-Pascual F, Laranjinha J, Radi R, Lamas S. Critical role of hydrogen 
peroxide signaling in the sequential activation of p38 mapk and enos in laminar shear 
stress. Free Radical Biology and Medicine. 2012;52:1093-1100 
150 
 
14. Van Buul JD, Fernandez-Borja M, Anthony EC, Hordijk PL. Expression and localization 
of nox2 and nox4 in primary human endothelial cells. Antioxidants & redox signaling. 
2005;7:308-317 
15. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular 
localizations of nox1 and nox4 in vascular smooth muscle cells. Arteriosclerosis, 
Thrombosis, and Vascular Biology. 2004;24:677-683 
16. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional 
analysis of nox4 reveals unique characteristics compared to other nadph oxidases. 
Cellular Signalling. 2006;18:69-82 
17. Evangelista AM, Thompson MD, Bolotina VM, Tong X, Cohen RA. Nox4- and nox2-
dependent oxidant production is required for vegf-induced serca cysteine-674 s-
glutathiolation and endothelial cell migration. Free radical biology & medicine. 
2012;53:10.1016/j.freeradbiomed.2012.1010.1546 
18. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. 
Expression of a functionally active gp91phox-containing neutrophil-type nad(p)h oxidase 
in smooth muscle cells from human resistance arteries: Regulation by angiotensin ii. 
Circulation Research. 2002;90:1205-1213 
19. Kansanen E, Jyrkkänen H-K, Levonen A-L. Activation of stress signaling pathways by 
electrophilic oxidized and nitrated lipids. Free Radical Biology and Medicine. 
2012;52:973-982 
20. Florczyk U, Jazwa A, Maleszewska M, Mendel M, Szade K, Kozakowska M, Grochot-
Przeczek A, Viscardi M, Czauderna S, Bukowska-Strakova K, Kotlinowski J, Jozkowicz 
A, Loboda A, Dulak J. Nrf2 regulates angiogenesis: Effect on endothelial cells, bone 
marrow-derived proangiogenic cells and hind limb ischemia. Antioxidants & redox 
signaling. 2014;20:1693-1708 
21. Ichihara S, Yamada Y, Liu F, Murohara T, Itoh K, Yamamoto M, Ichihara G. Ablation of 
the transcription factor nrf2 promotes ischemia-induced neovascularization by enhancing 
the inflammatory response. Arteriosclerosis, Thrombosis, and Vascular Biology. 
2010;30:1553-1561 
22. Tongers J, Knapp J-M, Korf M, Kempf T, Limbourg A, Limbourg FP, Li Z, Fraccarollo 
D, Bauersachs J, Han X, Drexler H, Fiedler B, Wollert KC. Heme oxygenase promotes 
progenitor cell mobilization, neovascularization, and functional recovery after critical 
hind-limb ischemia in mice. Cardiovascular Research. 2007 
23. Lee CW, Stabile E, Kinnaird T, Shou M, Devaney JM, Epstein SE, Burnett MS. 
Temporal patterns of gene expression after acute hindlimb ischemia in mice: Insights into 
the genomic program for collateral vessel development. Journal of the American College 
of Cardiology. 2004;43:474-482 
24. Han Z, Varadharaj S, Giedt RJ, Zweier JL, Szeto HH, Alevriadou BR. Mitochondria-
derived reactive oxygen species mediate heme oxygenase-1 expression in sheared 
endothelial cells. J.Pharmacol.Exp.Ther. 2009;329:94-101 
25. Braam B, de RR, Bluyssen H, Kemmeren P, Holstege F, Joles JA, Koomans H. Nitric 
oxide-dependent and nitric oxide-independent transcriptional responses to high shear 
stress in endothelial cells. Hypertension. 2005;45:672-680 
151 
 
26. Grochot-Przeczek A, Kotlinowski J, Kozakowska M, Starowicz K, Jagodzinska J, 
Stachurska A, Volger OL, Bukowska-Strakova K, Florczyk U, Tertil M, Jazwa A, Szade 
K, Stepniewski J, Loboda A, Horrevoets AJ, Dulak J, Jozkowicz A. Heme oxygenase-1 is 
required for angiogenic function of bone marrow-derived progenitor cells: Role in 
therapeutic revascularization. Antioxidants & redox signaling. 2014;20:1677-1692 
27. Pipp F, Heil M, Issbrucker K, Ziegelhoeffer T, Martin S, van den Heuvel J, Weich H, 
Fernandez B, Golomb G, Carmeliet P, Schaper W, Clauss M. Vegfr-1-selective vegf 
homologue plgf is arteriogenic: Evidence for a monocyte-mediated mechanism. 
Circulation Research. 2003;92:378-385 
28. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an 
antioxidant of possible physiological importance. Science. 1987;235:1043-1046 
29. Liu Y, Zhu B, Wang X, Luo L, Li P, Paty DW, Cynader MS. Bilirubin as a potent 
antioxidant suppresses experimental autoimmune encephalomyelitis: Implications for the 
role of oxidative stress in the development of multiple sclerosis. Journal of 
neuroimmunology. 2003;139:27-35 
30. Jansen T, Daiber A. Direct antioxidant properties of bilirubin and biliverdin. Is there a 
role for biliverdin reductase? Frontiers in Pharmacology. 2012;3 
31. Kobayashi A, Ishikawa K, Matsumoto H, Kimura S, Kamiyama Y, Maruyama Y. 
Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin ii–
induced cardiac hypertrophy. Hypertension. 2007;50:1040-1048 
32. Parfenova H, Leffler CW, Basuroy S, Liu J, Fedinec AL. Antioxidant roles of heme 
oxygenase, carbon monoxide, and bilirubin in cerebral circulation during seizures. 
Journal of Cerebral Blood Flow & Metabolism. 2012;32:1024-1034 
33. Bainbridge SA, Sidle EH, Smith GN. Direct placental effects of cigarette smoke protect 
women from pre-eclampsia: The specific roles of carbon monoxide and antioxidant 
systems in the placenta. Medical Hypotheses. 2005;64:17-27 
34. Eisenstein RS, Garcia-Mayol D, Pettingell W, Munro HN. Regulation of ferritin and 
heme oxygenase synthesis in rat fibroblasts by different forms of iron. Proceedings of the 
National Academy of Sciences. 1991;88:688-692 
35. Barañano DE, Wolosker H, Bae B-I, Barrow RK, Snyder SH, Ferris CD. A mammalian 
iron atpase induced by iron. Journal of Biological Chemistry. 2000;275:15166-15173 
36. Knutson MD, Vafa MR, Haile DJ, Wessling-Resnick M. Iron loading and 
erythrophagocytosis increase ferroportin 1 (fpn1) expression in j774 macrophages. 2003. 
37. Ferris CD, Jaffrey SR, Sawa A, Takahashi M, Brady SD, Barrow RK, Tysoe SA, 
Wolosker H, Baranano DE, Dore S, Poss KD, Snyder SH. Haem oxygenase-1 prevents 
cell death by regulating cellular iron. Nat Cell Biol. 1999;1:152-157 
38. Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K, Kimura H, Liu YV, Zhang H, 
Strazza M, Rey S, Savino L, Zhou YF, McDonald KR, Na Y, Vandiver S, Rabi A, 
Shaked Y, Kerbel R, Lavallee T, Semenza GL. Effects of aging and hypoxia-inducible 
factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb 
ischemia. Circ Res. 2007;101:1310-1318 
39. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, 
Campochiaro PA, Semenza GL. Cell type-specific regulation of angiogenic growth factor 
152 
 
gene expression and induction of angiogenesis in nonischemic tissue by a constitutively 
active form of hypoxia-inducible factor 1. Circ Res. 2003;93:1074-1081 
40. Patel TH, Kimura H, Weiss CR, Semenza GL, Hofmann LV. Constitutively active hif-
1alpha improves perfusion and arterial remodeling in an endovascular model of limb 
ischemia. Cardiovasc Res. 2005;68:144-154 
41. Hou HH, Cheng SL, Liu HT, Yang FZ, Wang HC, Yu CJ. Elastase induced lung 
epithelial cell apoptosis and emphysema through placenta growth factor. Cell Death Dis. 
2013;4:e793 
42. Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD, Kalra VK, 
Malik P. Placenta growth factor activates monocytes and correlates with sickle cell 
disease severity. Blood. 2003;102:1506-1514 
43. Ikeda Y, Tajima S, Yoshida S, Yamano N, Kihira Y, Ishizawa K, Aihara K-i, Tomita S, 
Tsuchiya K, Tamaki T. Deferoxamine promotes angiogenesis via the activation of 
vascular endothelial cell function. Atherosclerosis. 2011;215:339-347 
44. Chekanov VS, Zargarian M, Baibekov I, Karakozov P, Tchekanov G, Hare J, 
Nikolaychik V, Bajwa T, Akhtar M. Deferoxamine-fibrin accelerates angiogenesis in a 
rabbit model of peripheral ischemia. Vascular Medicine. 2003;8:157-162 
45. Zhao B, Cai J, Boulton M. Expression of placenta growth factor is regulated by both vegf 
and hyperglycaemia via vegfr-2. Microvascular Research. 2004;68:239-246 
46. Fujii T, Yonemitsu Y, Onimaru M, Inoue M, Hasegawa M, Kuwano H, Sueishi K. Vegf 
function for upregulation of endogenous plgf expression during fgf-2-mediated 
therapeutic angiogenesis. Atherosclerosis. 2008;200:51-57 
47. Jin Z-G, Ueba H, Tanimoto T, Lungu AO, Frame MD, Berk BC. Ligand-independent 
activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates 
activation of endothelial nitric oxide synthase. Circulation Research. 2003;93:354-363 
48. dela Paz NG, Walshe TE, Leach LL, Saint-Geniez M, D'Amore PA. Role of shear-stress-














The following appendix contains preliminary data from experiments that were carried out in 
studies that were either not pursued further, or were on going at the time of writing. 
  
Figure 1. Shear stress increases iron response protein binding to RNA iron response elements. In 
endothelial cells cocultured with smooth muscle cells FSS induced an increase in IRP binding 
similar to that of iron chelation with DFO (100 µM). FSS had no effect on IRP binding in smooth 
muscle cells. These data support the hypothesis that FSS induces a reduction in the labile pool of 






Figure 2. Effects of TNF-α on PLGF expression in endothelial monoculture. Endothelial 
monocultures were treated with 1-20 ng/ml TNF-α media was collected at the indicated times and 
assayed for PLGF protein as described above data was normalized to media total protein. All 






Figure 3. FAC partially restores PLGF expression during TNF-α treatment. Endothelial 
monocultures were treated as above with TNF-α in a separate group FAC was also added to the 
culture media cells were incubated for 24h at which time media was collected and analyzed for 
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Figure 4. PLGF expression is up regulated in endothelial cells sourced from donors diagnosed 
with type II diabetes ante mortem. Cells were grown to confluence in 75 cm
2
 flasks at which time 
cells were trypsinized and seeded at a density of 3x10
5
 cells/well. Cell cultures were grown to 
confluence in 6 well plates. Culture media was replaced for reduced serum media for 24h and 





























Figure 5. Effect of glucose concentration on PLGF in endothelial cells. Control donor endothelial 
cells were cultured as above. Media was supplemented with glucose to a final concentration of 15 
mM in serum reduced media for 24h. 15 mM glucose had no significant effect on PLGF protein 




Figure 6. PLGF expression is up regulated in smooth muscle cells sourced from donors diagnosed 
with type II diabetes ante mortem. Samples were prepared as described above for endothelial 
cells. Donors 0 and 1 showed significantly higher PLGF protein in their culture media, compared 




































Figure 7. Donor Control 1 cells were cultured as outlined above in 6 well plates. Culture media 
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